{"gene":"TREX1","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1999,"finding":"TREX1 encodes a 304-amino acid protein with three conserved motifs generating the exonuclease active site, most closely related to proofreading exonucleases of bacterial replicative DNA polymerases. Recombinant TREX1 expressed in E. coli is an active 3'→5' DNA exonuclease with greatest activity on partial duplex DNA containing 3' mismatched nucleotides; no activity was detected on single-stranded RNA or RNA-DNA partial duplexes.","method":"Recombinant protein expression in E. coli, in vitro exonuclease activity assays with ssDNA, partial duplex, and mispaired oligonucleotide substrates","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro with purified recombinant protein, multiple substrate types tested, foundational biochemical characterization","pmids":["10391904"],"is_preprint":false},{"year":2001,"finding":"TREX1 (mouse) exists as a homodimer with robust 3'→5' exonuclease activity. Steady-state kinetics on ssDNA oligonucleotides yielded kcat ~22 s⁻¹ and KM ~19 nM for mouse Trex1. Competition assays with heparin and partial duplex DNA substrates established substrate structure preferences for 3' nucleotide excision.","method":"Recombinant protein expression and purification from E. coli, steady-state kinetic analysis, heparin competition assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro with purified protein, rigorous kinetic characterization with multiple methods","pmids":["11279105"],"is_preprint":false},{"year":2004,"finding":"Gene-targeted Trex1⁻/⁻ mice are viable but develop inflammatory myocarditis leading to cardiomyopathy and circulatory failure, establishing that TREX1 loss-of-function in vivo causes inflammatory disease rather than increased mutation frequency or cancer.","method":"Gene targeting (knockout mice), histopathology, survival analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic KO with defined inflammatory phenotype, replicated in subsequent studies","pmids":["15254239"],"is_preprint":false},{"year":2006,"finding":"TREX1 is the major mammalian 3'→5' DNA exonuclease encoded by AGS1; AGS-causing mutations abrogate TREX1 enzyme activity, and similar loss-of-function in Trex1⁻/⁻ mice leads to an inflammatory phenotype, implicating TREX1 in processing or clearing anomalous DNA structures to prevent innate immune triggering.","method":"Mutational analysis, exonuclease activity assays of patient-derived mutations, Trex1⁻/⁻ mouse model","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — enzyme activity assays on disease-associated mutants combined with genetic mouse model, replicated across labs","pmids":["16845398"],"is_preprint":false},{"year":2006,"finding":"TREX1 (but not TREX2) is a component of the endoplasmic reticulum-associated SET complex. TREX1 binds SET, colocalizes and translocates with the SET complex to the nucleus during granzyme A-mediated apoptosis, where it works in concert with NM23-H1 to degrade genomic DNA: after NM23-H1 nicks DNA, TREX1 removes nucleotides from the nicked 3' end. Silencing TREX1 inhibits DNA damage and cell death in response to perforin/granzyme A but not perforin/granzyme B.","method":"Co-immunoprecipitation, colocalization by immunofluorescence, siRNA knockdown, cell death assays with perforin/granzyme A treatment","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, functional siRNA knockdown with specific phenotypic readout, multiple orthogonal methods","pmids":["16818237"],"is_preprint":false},{"year":2007,"finding":"Crystal structure of dimeric mouse TREX1 in substrate and product complexes with ssDNA and deoxyadenosine monophosphate reveals specific active-site interactions with the 3'-terminal nucleotide, providing molecular basis for specificity. Three AGS-associated TREX1 mutants show 4–35,000-fold reduced enzyme activity. The structure reveals an 8-amino acid polyproline II helix on the surface suggesting a mechanism for interactions with other protein complexes.","method":"X-ray crystallography, site-directed mutagenesis, in vitro exonuclease activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure at substrate/product complex level combined with mutagenesis and activity assays in one rigorous study","pmids":["17293595"],"is_preprint":false},{"year":2007,"finding":"Crystal structures of dimeric murine TREX1 complexed with a nucleotide product and ssDNA substrate reveal sequence preferences for certain DNA motifs (GAG, ACA, CTGC). A conserved proline-rich region (PPPVPRPP) on the TREX1 surface interacts with WW2 domain of transcription elongation factor CA150, confirmed by NMR titration and co-immunoprecipitation with full-length TREX1. Nuclear localization of TREX1 requires loss of a C-terminal segment (leucine-rich repeat 3).","method":"X-ray crystallography, NMR titration, co-immunoprecipitation, confocal microscopy","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with NMR and Co-IP, multiple orthogonal methods in one study","pmids":["17355961"],"is_preprint":false},{"year":2007,"finding":"TREX1 acts in concert with the SET complex in granzyme A-mediated apoptosis. A heterozygous D18N mutation in TREX1 renders recombinant mutant TREX1 homodimers enzymatically inactive; wild-type/D18N heterodimers retain residual activity. Lymphoblastoid cells with D18N are significantly less sensitive to granzyme A-mediated cell death.","method":"Recombinant protein preparation, in vitro exonuclease activity assays, granzyme A cell death assays in patient-derived lymphoblastoid cells","journal":"Journal of molecular medicine","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — recombinant enzyme biochemistry plus cell-based functional assay, single lab but two orthogonal methods","pmids":["17440703"],"is_preprint":false},{"year":2007,"finding":"TREX1 is an essential negative regulator of the IFN-stimulatory DNA (ISD) response. In Trex1-deficient cells, single-stranded DNA derived from endogenous retroelements accumulates. TREX1 can metabolize reverse-transcribed DNA, preventing chronic activation of innate immune signaling. Genetic pathway analysis links Trex1 deficiency to lethal autoimmunity through the ISD pathway.","method":"Genetic screen, Trex1⁻/⁻ mouse cells, ISD pathway reporter assays, DNA accumulation analysis, epistasis via Trex1 KO rescue experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including genetic pathway placement, cell-intrinsic functional assays, replicated across labs","pmids":["18724932"],"is_preprint":false},{"year":2007,"finding":"Dominant mutations in TREX1 (D200N and D18N) associated with autoimmune disease exhibit completely deficient dsDNA degradation activity while retaining partial ssDNA degradation activity. The dominant mutant heterodimers (WT/D200N and WT/D18N) inhibit the dsDNA degradation activity of WT TREX1 enzyme, explaining the dominant phenotype. The recessive R114H homodimer has dysfunctional dsDNA and ssDNA activities but does not inhibit WT enzyme.","method":"In vitro exonuclease activity assays with nicked dsDNA and ssDNA substrates using recombinant homo- and heterodimers","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro biochemical reconstitution with disease-relevant mutant proteins, single lab but multiple substrate types","pmids":["18805785"],"is_preprint":false},{"year":2007,"finding":"Trex1, ordinarily associated with the endoplasmic reticulum, relocalizes to the S-phase nucleus after gamma irradiation or hydroxyurea treatment. Trex1-deficient cells show chronic ATM-dependent checkpoint activation even without exogenous stress, correlated with persistent ssDNA produced in S phase accumulating in the ER. Trex1 degrades ssDNA arising from aberrant replication intermediates to prevent chronic checkpoint signaling.","method":"Immunofluorescence/subcellular fractionation, gamma irradiation, hydroxyurea treatment, ATM inhibition, Trex1⁻/⁻ cells","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiments with functional consequence, genetic KO with defined molecular phenotype, multiple orthogonal methods","pmids":["18045533"],"is_preprint":false},{"year":2008,"finding":"X-ray crystal structures of TREX1 apoprotein, dominant AGS/FCL mutants (D200H, D200N, D18N) and recessive mutant (V201D) reveal mechanism of catalytic impairment: D200H and D200N lose coordination of one active-site metal and the catalytic histidine (H195) is trapped in a non-catalytic conformation; D18N and V201D bind both metals but with inter-metal distances non-optimal for catalysis. All mutants show reduced mobility of catalytic histidine.","method":"X-ray crystallography of multiple mutant TREX1 proteins","journal":"DNA repair","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures of multiple disease mutants providing mechanistic insight, single lab but comprehensive structural analysis","pmids":["22071149"],"is_preprint":false},{"year":2008,"finding":"Lithium and sodium cations inhibit TREX1 exonuclease activity by competing with catalytic magnesium/manganese for the two metal-binding sites, inducing subtle active-site rearrangements. X-ray structures with Li⁺ and Na⁺ in complex with a nucleotide product explain this inhibition mechanism. Mutagenesis of His124 (highly conserved in DEDDh family) confirmed its requirement for TREX1 activity, identifying it as a catalytic residue.","method":"X-ray crystallography at 2.1 Å and 2.3 Å, in vitro exonuclease activity assays, site-directed mutagenesis of His124","journal":"Protein science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures combined with mutagenesis and activity assays, single lab but multiple orthogonal approaches","pmids":["18780819"],"is_preprint":false},{"year":2010,"finding":"The cytosolic exonuclease TREX1 suppresses interferon triggered by HIV-1 infection. TREX1 binds cytosolic HIV DNA and degrades excess HIV DNA that would otherwise activate type I interferon via a TBK1/STING/IRF3-dependent pathway. In Trex1⁻/⁻ mouse cells and TREX1-knockdown human CD4⁺ T cells and macrophages, cytosolic HIV DNA accumulates and HIV infection induces type I interferon that inhibits HIV replication.","method":"Trex1⁻/⁻ mouse cells, siRNA knockdown in human T cells/macrophages, co-immunoprecipitation of TREX1 with HIV DNA, interferon induction assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional assays in multiple cell types (mouse KO + human RNAi), Co-IP of TREX1 with HIV DNA, pathway dissection via TBK1/STING/IRF3","pmids":["20871604"],"is_preprint":false},{"year":2010,"finding":"TREX1 expression is induced by genotoxic stress (UV light, benzo(a)pyrene, hydrogen peroxide) through an AP-1-dependent transcriptional mechanism. The mouse and human trex1 promoters contain AP-1 binding sites recognized by c-Fos and c-Jun; mutational inactivation of the AP-1 site abolishes induction. Upon genotoxic stress, TREX1 also translocates to the nucleus. TREX1-deficient cells show reduced recovery from UV/benzo(a)pyrene-induced replication inhibition.","method":"RT-PCR, promoter reporter assays, EMSA, c-fos/c-jun null cells, siRNA knockdown, immunofluorescence localization","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (reporter assays, EMSA, KO cells, localization), single lab","pmids":["20511593"],"is_preprint":false},{"year":2011,"finding":"TREX1 degrades plasmid and chromatin dsDNA by locating endonuclease-generated 3' termini. Dominant TREX1 mutants (D18N, D200N, D200H) retain intact DNA binding but have dysfunctional active-site chemistry; competition assays demonstrate that the dominant mutants block access of WT TREX1 to DNA 3' termini through metal-dependent ssDNA binding in catalytically inactive active sites. Residues Arg-174 and Lys-175 act with Arg-128 to facilitate dsDNA melting for ssDNA loading.","method":"In vitro exonuclease assays with plasmid and chromatin dsDNA, competition assays with dominant mutant and WT TREX1 proteins","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous biochemical reconstitution with multiple substrate types and mutant proteins, mechanistic dissection of dominant inhibition","pmids":["21808053"],"is_preprint":false},{"year":2011,"finding":"TREX1 R114H is a common AGS mutation; the R114H/R114H homodimer has 23-fold reduced ssDNA exonuclease activity. Compound heterodimers R114H/D201ins and R114H/A124ins exhibit 10-fold higher activity than the R114H homodimer, because Arg-114 residues from D201ins and A124ins protomers contribute to catalysis in the opposing R114H protomer across the dimer interface.","method":"Recombinant preparation of homo- and heterodimers, ssDNA and dsDNA exonuclease activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with disease-relevant compound heterodimers, mechanistic dissection of dimer interface contributions","pmids":["21937424"],"is_preprint":false},{"year":2012,"finding":"Trex1 regulates lysosomal biogenesis and activates a subset of interferon-stimulated genes (ISGs/antiviral genes) independently of type I interferon. This interferon-independent activation in Trex1-deficient cells requires STING, TBK1, IRF3, and IRF7. Trex1-deficient cells also have an expanded lysosomal compartment, altered subcellular localization of TFEB, and diminished mTORC1 activity.","method":"Trex1⁻/⁻ mouse cells, STING/TBK1/IRF3/IRF7 genetic epistasis, transcriptomic profiling, lysosomal compartment analysis","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with multiple pathway components, multiple orthogonal cellular readouts, single lab","pmids":["23160154"],"is_preprint":false},{"year":2013,"finding":"TREX1 C-terminal region controls cellular localization through ubiquitination. A highly conserved sequence in the CTR is required for ubiquitination at multiple lysine residues through a non-canonical ubiquitin linkage. Ubiquilin 1 was identified by proteomics as a TREX1 CTR-interacting protein (confirmed in vitro and in vivo), and ubiquilin 1 localizes TREX1 to cytosolic punctate structures dependent on the TREX1 CTR and catalytic core lysines. Disease-causing catalytically competent TREX1 mutants show differential ubiquitination and altered ubiquilin 1 co-localization.","method":"Deletion construct transfection, mass spectrometry proteomics, co-immunoprecipitation, in vitro binding assay, cotransfection co-localization","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — proteomic identification plus Co-IP validation, functional localization experiments with multiple constructs, single lab","pmids":["23979357"],"is_preprint":false},{"year":2013,"finding":"Oxidized DNA containing 8-hydroxyguanosine (8-OHG) is resistant to TREX1-mediated degradation. This resistance potentiates cGAS/STING-dependent cytosolic immune recognition, as oxidative modifications reduce TREX1's ability to degrade the DNA. 8-OHG arises in pathogen DNA during lysosomal ROS exposure and in NET DNA during oxidative burst.","method":"In vitro TREX1 degradation assays with oxidized vs. unmodified DNA, cytosolic DNA sensing assays, cell-based immune activation experiments","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct in vitro biochemical assay of TREX1 activity on oxidized substrate combined with cellular immune sensing assays","pmids":["23993650"],"is_preprint":false},{"year":2014,"finding":"TREX1 deficiency triggers cell-autonomous innate immune activation that is completely dependent on cGAS. Knockout of cGAS in TREX1-deficient cells abrogates spontaneous induction of interferon-stimulated genes, placing cGAS upstream of the type I IFN response in TREX1-deficient settings.","method":"TREX1/cGAS double-knockout cells, ISG expression assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean double-KO genetic epistasis placing cGAS as required sensor, replicated by subsequent independent work","pmids":["24813208"],"is_preprint":false},{"year":2014,"finding":"TREX1 directly interacts with PARP1 via PARP1's N-terminal zinc finger domains. This interaction occurs after nuclear translocation of TREX1 in response to DNA damage. TREX1 may contribute to stabilization of PARP1 levels and its activity during the DNA damage response.","method":"Mass spectrometry, co-immunoprecipitation assays, in vivo overexpression, domain mapping","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP confirmed by MS, domain mapping, but functional claims (stabilization) are partial/suggestive, single lab","pmids":["25278026"],"is_preprint":false},{"year":2015,"finding":"TREX1 is also an exoribonuclease that degrades single-stranded RNA but not double-stranded RNA. The AGS disease mutant TREX1-D200N is defective in RNA degradation. TREX1 activity is inhibited by stretches of pyrimidine residues; TREX1 is active on native tRNA substrates. The substrate-binding site is open enough to accommodate the 2'-OH of RNA.","method":"In vitro exoribonuclease assays with purified TREX1, kinetic measurements, mutant protein analysis, structural analysis of published crystal structures","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro biochemical reconstitution with purified protein and multiple RNA substrates, kinetics, disease mutant analysis","pmids":["25855793"],"is_preprint":false},{"year":2015,"finding":"Crystal structure of TREX1 D18N in complex with dsDNA reveals a novel DNA-unwinding mechanism where TREX1 uses specific residues to separate polynucleotide strands for ssDNA loading into the active site. TREX1 D18N has dysfunctional dsDNA-degrading activity. TREX1 D18N knock-in mice develop systemic lupus-like inflammation with autoantibodies to dsDNA and immune complex deposition, demonstrating that dysfunctional dsDNA degradation alone is sufficient to cause lupus-like disease.","method":"X-ray crystallography of TREX1 D18N-dsDNA complex, knock-in mouse model, immunohistochemistry, autoantibody assays","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with mechanistic insight combined with knock-in mouse model with defined disease phenotype, multiple orthogonal methods","pmids":["25848017"],"is_preprint":false},{"year":2015,"finding":"TREX1 C terminus suppresses immune activation independently of nuclease activity by interacting with the ER oligosaccharyltransferase (OST) complex and stabilizing its catalytic integrity. C-terminal frameshift mutations (as in RVCL) dysregulate the OST complex leading to free glycan release from dolichol carriers and immune activation. OST inhibition with aclacinomycin corrects glycan and immune defects in TREX1 frameshift mutant cells and mice.","method":"Co-immunoprecipitation of TREX1 with OST complex, glycan analysis, TREX1 KO and frameshift knock-in mice, patient lymphoblasts, aclacinomycin pharmacological rescue","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP of protein complex, multiple genetic models (KO + knock-in mice + patient cells), pharmacological rescue, multiple orthogonal methods","pmids":["26320659"],"is_preprint":false},{"year":2015,"finding":"cGAS is required for lethal autoimmune disease in Trex1⁻/⁻ mice. Trex1⁻/⁻ cGAS⁻/⁻ double knockout mice are completely protected from lethality, show dramatically reduced tissue inflammation, and fail to develop autoantibodies, placing cGAS as a key driver of Trex1-deficiency-associated autoimmune disease.","method":"Double-knockout mouse genetics, histopathology, survival analysis, autoantibody measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean double-KO genetic epistasis in vivo with multiple disease readouts, replicated independently","pmids":["26223655"],"is_preprint":false},{"year":2017,"finding":"DNA exonuclease TREX1 is induced by radiation doses above 12–18 Gy in cancer cells and attenuates immunogenicity by degrading cytosolic double-stranded DNA that accumulates upon radiation. Cytosolic DNA stimulates IFN-β secretion via cGAS and STING activation. At doses that do not induce TREX1, repeated irradiation amplifies IFN-β production, drives BATF3-dependent DC recruitment and CD8⁺ T cell priming for abscopal tumor rejection.","method":"Radiation dose–response experiments in cancer cells, siRNA knockdown, cGAS/STING pathway reporter assays, mouse tumor models, T cell depletion experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods in vitro and in vivo, functional knockdown, pathway dissection, widely replicated concept","pmids":["28598415"],"is_preprint":false},{"year":2017,"finding":"TREX1 suppresses L1 retrotransposon activity through a nuclease-independent mechanism. TREX1 interacts with L1 ORF1p protein and alters its intracellular localization, triggering ORF1p depletion and reducing L1-mediated nicking of genomic DNA. AGS-associated TREX1 mutants competent for DNA exonuclease activity are deficient in inducing ORF1p depletion.","method":"Co-immunoprecipitation, immunofluorescence co-localization, L1 retrotransposition and genomic nicking assays, AGS mutant analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP and functional retrotransposition assays, mechanistic claim of protein destabilization, single lab with two orthogonal methods","pmids":["28334850"],"is_preprint":false},{"year":2017,"finding":"During mitosis, TREX1 is predominantly phosphorylated at C-terminal Serine-261 by Cyclin B/CDK1, and dephosphorylated at mitotic exit likely by PP1/PP2-type phosphatases. Mitotic phosphorylation does not affect DNase activity but phosphomimetic mutations disrupt TREX1 interaction with OST subunit RPN1 and elevate a glyco-gene expression signature. Thus cell-cycle-dependent phosphorylation regulates TREX1's OST-interacting function.","method":"Mass spectrometry identification of phosphorylation site, CDK1 inhibition, phosphomimetic mutant co-immunoprecipitation with RPN1, RNA-seq of Trex1⁻/⁻ MEFs with WT or phospho-mutants","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — MS identification of PTM + Co-IP with mutants + transcriptomic functional readout, multiple orthogonal approaches, single lab","pmids":["28297665"],"is_preprint":false},{"year":2017,"finding":"TREX1 transcription is induced by IFN-γ in primary macrophages via STAT1 binding to IFN-γ activation site (GAS) boxes in the Trex1 promoter, and c-Jun (but not c-Fos, JunB, or CREB) binding to an AP-1 box. This was confirmed using STAT1 KO macrophages and EMSA/ChIP assays.","method":"EMSA, ChIP, transient transfection reporter assays, STAT1 KO macrophages, promoter mutational analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP and EMSA with genetic KO confirmation, promoter mutagenesis, multiple orthogonal approaches","pmids":["21239708"],"is_preprint":false},{"year":2018,"finding":"Crystal structures of TREX1 complexed with various DNA substrates (L-shaped, Y-shaped DNA) reveal that the Leu24-Pro25-Ser26 cluster serves to cap the non-scissile 5'-end for precise removal of short 3'-overhangs or to wedge into dsDNA for further digestion along the duplex. Arg128 shows consistent interaction patterns with the non-scissile strand across all structures. TREX1 can degrade dsDNA to completion.","method":"X-ray crystallography of multiple TREX1-DNA complexes, in vitro biochemical dsDNA degradation assays","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple crystal structures with different substrates combined with biochemical validation, single lab but comprehensive structural analysis","pmids":["29734329"],"is_preprint":false},{"year":2018,"finding":"Tumor-derived exosomes from irradiated cancer cells (RT-TEX) transfer dsDNA to dendritic cells and stimulate STING-dependent IFN-β production. The IFN-stimulatory dsDNA cargo of RT-TEX is regulated by TREX1 expression in the parent cancer cells, demonstrating that TREX1 controls the immunostimulatory DNA content packaged into exosomes.","method":"Exosome purification and characterization, TREX1 knockdown in cancer cells, DC stimulation assays, in vivo tumor vaccination experiments","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — functional exosome transfer assays with TREX1 KD, in vivo validation, single lab","pmids":["29907693"],"is_preprint":false},{"year":2021,"finding":"cGAS-DNA phase separation inhibits TREX1-mediated DNA degradation. cGAS phase separation forms a selective environment that suppresses TREX1 catalytic function and restricts DNA degradation to the droplet periphery. An AGS-associated TREX1 mutation increases TREX1 penetration into the repressive droplet interior, specifically impairing degradation of phase-separated DNA.","method":"In vitro phase separation reconstitution, TREX1 activity assays on phase-separated DNA, confocal imaging of droplets, disease mutant analysis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of phase separation with direct enzymatic activity measurements, disease mutant mechanistic analysis, single lab with multiple methods","pmids":["33606975"],"is_preprint":false},{"year":2021,"finding":"The ER-associated nuclease TREX1 inhibits cGAS activation at micronuclei by degrading micronuclear DNA upon micronuclear envelope rupture. The ER accesses ruptured micronuclei enabling TREX1 nucleolytic attack. TREX1 mutations that cause immune disease untether TREX1 from the ER, disrupt localization to micronuclei, diminish micronuclear DNA damage, and enhance cGAS activation. ER tethering is thus mechanistically required for TREX1's role in preventing innate immune activation at micronuclei.","method":"Micronuclei purification, TREX1 localization by immunofluorescence, ER membrane tracking, disease mutant analysis, cGAS activation assays, functional nuclease activity at micronuclei","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization experiments with functional consequence, disease mutant mechanistic analysis, micronuclei purification approach, multiple orthogonal methods","pmids":["33476576"],"is_preprint":false},{"year":2021,"finding":"TREX1 translocates into the nucleus after nuclear envelope rupture and is required to induce DNA damage in this context. Inside the mammary duct, cellular crowding leads to nuclear envelope ruptures that generate TREX1-dependent DNA damage, driving progression of in situ carcinoma to the invasive stage.","method":"Live-cell imaging, TREX1 nuclear translocation assays after NE rupture, TREX1 KO/knockdown, in vivo mammary duct compression models, DNA damage markers","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct localization tied to functional DNA damage consequence, KO with specific phenotypic readout, multiple orthogonal methods","pmids":["34551315"],"is_preprint":false},{"year":2022,"finding":"Crystal structures of human TREX1 in apo (1.25 Å) and DNA-bound (2.2 Å) conformations establish complete solvation of the exonuclease active site and identify specific substitutions involved in DNA recognition. Mapping of all human disease-associated mutations identifies distinct categories affecting enzymatic function, protein stability, and interaction with cGAS-DNA liquid droplets.","method":"X-ray crystallography at 1.25 Å (apo) and 2.2 Å (DNA complex), comprehensive mutation mapping","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structures of human (not mouse) protein providing complete active-site model, comprehensive disease mutation analysis","pmids":["35879334"],"is_preprint":false},{"year":2022,"finding":"TREX1 degrades the 3' end of the small excised damage-containing DNA oligonucleotides (~30 nt, sedDNA) produced by nucleotide excision repair. TREX1 knockdown increases sedDNA levels and their association with NER proteins TFIIH and RPA; overexpression of WT but not nuclease-inactive TREX1 diminishes sedDNA levels. Purified TREX1 efficiently degrades DNA 3' of UV photoproducts in sedDNA. TREX1 modulation does not affect NER efficiency or cell survival.","method":"RNAi screen, TREX1 knockdown/overexpression in UV-irradiated cells, in vitro assays with purified TREX1 and synthetic sedDNA substrates","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro reconstitution with purified enzyme plus cell-based knockdown/overexpression, two orthogonal approaches identifying a new TREX1 substrate","pmids":["35357486"],"is_preprint":false},{"year":2022,"finding":"Purified human TREX1 repairs 3'-PUA-peptide/protein DNA-protein cross-links (DPCs) arising from abasic sites, acting as an exonuclease on the 3'-PUA-modified terminus. TREX1 can directly repair 3'-PUA-histone DPCs but not 3'-PUA-PARP1 DPCs unless proteolysis occurs first. Kinetic constants were determined for DPC repair by TREX1.","method":"In vitro enzymatic assays with purified recombinant TREX1 and synthetic 3'-PUA-peptide adducts, kinetic analysis, histone and PARP1 DPC substrates","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro reconstitution with purified enzyme on defined synthetic substrates, kinetic characterization, single lab","pmids":["35349719"],"is_preprint":false},{"year":2023,"finding":"TREX1 can digest ssRNA and DNA/RNA hybrids but not dsRNA. Crystal structures of TREX1-RNA product and TREX1-nucleotide complexes show 2'-OH does not impose steric hindrance for RNA recognition. MD simulations and binding affinity measurements with synthetic DNA-RNA junctions demonstrate that 2'-OH-mediated intra-chain hydrogen bonding in RNA increases conformational rigidity, reducing TREX1 binding affinity and catalytic cleavage efficiency.","method":"In vitro exonuclease activity assays, X-ray crystallography, all-atom molecular dynamics simulations, binding affinity measurements","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures combined with MD simulations and biochemical activity measurements, multiple orthogonal approaches","pmids":["37870446"],"is_preprint":false},{"year":2023,"finding":"TREX1 degrades cytoplasmic mitochondrial DNA (mtDNA) released during influenza virus infection, preventing cGAS/STING-mediated antiviral sensing. Infection triggers release of mtDNA into the cytoplasm; TREX1 metabolizes this self-DNA, thereby preventing amplification of antiviral signaling and thus aiding viral replication.","method":"CRISPR-based genome-wide fitness screen during influenza infection, TREX1 KO cells, mtDNA accumulation assays, cGAS/STING pathway reporters","journal":"Cell host & microbe","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genome-wide CRISPR screen plus KO validation with specific pathway readout and mtDNA substrate identification, single lab","pmids":["37652009"],"is_preprint":false},{"year":2024,"finding":"TREX1 expression is coordinately induced with STING by autocrine IFN and downstream STAT1 in cancer cells, acting as a negative feedback mechanism. TREX1 restrains STING-dependent nucleic acid sensing via its catalytic DNA-degrading function. TREX1 inactivation in cancer cells unleashes STING-IFN signaling, recruiting T cells and NK cells and cooperating with PD-1 blockade.","method":"Cancer cell TREX1 KO/knockdown, STING pathway reporter assays, in vivo mouse tumor models with immune cell depletion, RNA-seq, combination immunotherapy experiments","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple cancer cell KO models in vitro and in vivo, mechanistic pathway dissection (STAT1→TREX1 induction), immune cell depletion experiments","pmids":["38227896"],"is_preprint":false},{"year":2024,"finding":"TREX1 C-terminal frameshift variants associated with RVCL mislocalize to the nucleus (due to deletion of the ER-anchoring domain) and inhibit homology-directed repair (HDR), causing DNA deletions. RVCL TREX1 mutants increase cellular vulnerability to DNA damage induced by chemotherapy and cytokines, and cells expressing these mutants are depleted in vivo. Mechanistic studies in Drosophila, mice, and human cells confirm nuclear TREX1 causes DNA damage and disrupts HDR.","method":"RVCL patient cell analysis, mouse models, Drosophila genetics, CRISPR HDR assays, DNA damage marker analysis, PARP inhibitor sensitivity assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multi-organism validation (human, mouse, Drosophila) with multiple orthogonal assays linking nuclear TREX1 mislocalization to HDR deficiency and DNA damage","pmids":["38824133"],"is_preprint":false},{"year":2024,"finding":"TREX1 degrades single-stranded and linearized double-stranded DNA repair templates used for CRISPR-Cas9-mediated HDR, reducing HDR efficiency. TREX1 expression level serves as a biomarker for HDR efficiency across cell types. TREX1 knockout or use of chemically protected ssDNA templates rescues HDR efficiency by 2- to 8-fold in TREX1-expressing cells including primary T cells and hematopoietic stem/progenitor cells.","method":"Genome-wide CRISPR screen for HDR suppressors in Fanconi anemia lymphoblasts, TREX1 KO in multiple cell types, HDR efficiency assays with protected vs. unprotected templates","journal":"Nature biotechnology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide screen plus KO validation in multiple cell types with direct HDR mechanistic readout, functional rescue with protected templates","pmids":["39134754"],"is_preprint":false},{"year":2014,"finding":"Arg-62 residues of TREX1 extend across the dimer interface into the active site of the opposing protomer to coordinate substrate DNA and affect catalysis in trans. The TREX1(R62A/R62A) homodimer exhibits ~50-fold reduced ssDNA and dsDNA degradation. Dominant mutants (D18H, D18N, D200H, D200N) compound heterodimers with R62A in the opposing protomer show higher activity than the corresponding homodimers, demonstrating that Arg-62 provides structural elements required for full catalytic activity in the opposing protomer.","method":"Site-directed mutagenesis, recombinant homo- and heterodimer preparation, in vitro ssDNA and dsDNA exonuclease activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro biochemical reconstitution with multiple mutant combinations, mechanistic dissection of dimer interface trans-catalysis","pmids":["24616097"],"is_preprint":false}],"current_model":"TREX1 is an ER-anchored, dimeric 3'→5' DNA exonuclease (and weak exoribonuclease) that constitutively degrades cytosolic ssDNA, dsDNA, reverse-transcribed DNA, RNA, DNA/RNA hybrids, and NER-excised oligonucleotides to prevent cGAS-STING-dependent innate immune activation; its ER tethering—regulated by a C-terminal transmembrane domain subject to mitotic CDK1 phosphorylation and ubiquitination—directs it to ruptured micronuclei and nuclear envelope rupture sites where it resects DNA to limit cGAS access, while a nuclease-independent C-terminal interaction with the oligosaccharyltransferase (OST) complex suppresses glycan-driven immune activation, and loss-of-function or mislocalization of TREX1 results in cytosolic DNA accumulation sensed by cGAS, driving type I IFN-dependent autoimmune disease."},"narrative":{"mechanistic_narrative":"TREX1 is the major mammalian 3'→5' DNA exonuclease, a homodimer with a DEDDh-family active site that constitutively degrades cytosolic DNA to prevent cell-autonomous innate immune activation [PMID:10391904, PMID:11279105, PMID:16845398]. Biochemically it excises 3'-terminal nucleotides from single-stranded DNA, nicked and blunt dsDNA, and reverse-transcribed DNA, processively melting and digesting duplex substrates to completion via residues including Arg128, Arg174/Lys175, and the Leu24-Pro25-Ser26 cap [PMID:18805785, PMID:21808053, PMID:29734329]; crystal structures of substrate/product complexes establish the molecular basis for 3'-nucleotide specificity and DNA strand separation [PMID:17293595, PMID:25848017, PMID:35879334]. The dimer interface is functionally integrated, with Arg62 and Arg114 acting in trans across protomers, which explains how dominant-negative disease heterodimers inactivate wild-type enzyme [PMID:21937424, PMID:24616097]. Beyond DNA, TREX1 is also an exoribonuclease degrading ssRNA and DNA/RNA hybrids but not dsRNA, with RNA's 2'-OH-driven rigidity reducing catalytic efficiency [PMID:25855793, PMID:37870446]. The enzyme functions as an essential negative regulator of the interferon-stimulatory DNA response: loss of TREX1 causes accumulation of endogenous retroelement-derived, micronuclear, and mitochondrial DNA that is sensed by cGAS, driving STING/TBK1/IRF3-dependent type I IFN and lethal autoimmunity, with cGAS deletion fully rescuing the Trex1⁻/⁻ phenotype [PMID:18724932, PMID:24813208, PMID:26223655, PMID:37652009]. TREX1 is normally ER-anchored through a C-terminal transmembrane domain; this tethering directs it to ruptured micronuclei and nuclear envelope rupture sites to resect exposed DNA and limit cGAS access, and disease mutations that untether the enzyme abolish this localization [PMID:33476576, PMID:34551315]. A separate, nuclease-independent C-terminal interaction with the ER oligosaccharyltransferase (OST) complex — regulated by mitotic CDK1 phosphorylation at Ser261 — stabilizes OST and suppresses glycan-driven immune activation [PMID:26320659, PMID:28297665]. TREX1 loss-of-function or C-terminal frameshift mutations cause Aicardi-Goutieres syndrome, familial chilblain lupus, systemic lupus-like disease, and retinal vasculopathy with cerebral leukodystrophy (RVCL), the latter through nuclear mislocalization that disrupts homology-directed repair [PMID:16845398, PMID:25848017, PMID:26320659, PMID:38824133].","teleology":[{"year":1999,"claim":"Established that TREX1 is an autonomous 3'→5' DNA exonuclease, defining the molecular activity that anchors all later biology.","evidence":"Recombinant protein from E. coli with in vitro exonuclease assays on multiple substrates","pmids":["10391904"],"confidence":"High","gaps":["No cellular substrate or physiological role identified","Initially reported no RNA activity, later revised"]},{"year":2001,"claim":"Showed TREX1 acts as a homodimer with rigorous kinetics and defined substrate-structure preferences, framing its enzymatic mechanism.","evidence":"Purified mouse Trex1, steady-state kinetics, heparin competition assays","pmids":["11279105"],"confidence":"High","gaps":["Dimer interface contributions to catalysis not yet resolved","No in vivo function"]},{"year":2004,"claim":"Demonstrated that TREX1 loss in vivo causes inflammatory disease rather than mutator/cancer phenotype, redirecting the field toward immune regulation.","evidence":"Trex1⁻/⁻ knockout mice, histopathology, survival analysis","pmids":["15254239"],"confidence":"High","gaps":["Molecular trigger of inflammation unknown","Sensor pathway not yet identified"]},{"year":2006,"claim":"Linked TREX1 to human Aicardi-Goutieres syndrome and to a SET-complex apoptotic DNA-degradation role, connecting enzyme activity to disease and to genomic DNA clearance.","evidence":"AGS mutation activity assays, Trex1⁻/⁻ mice, reciprocal Co-IP with SET/NM23-H1, granzyme A cell death assays","pmids":["16845398","16818237"],"confidence":"High","gaps":["Nature of the immune-triggering DNA species undefined","Relationship between apoptotic and homeostatic roles unclear"]},{"year":2007,"claim":"Provided crystal structures and the dominant-versus-recessive biochemical logic, explaining at atomic resolution why disease mutants lose activity and how dominant heterodimers poison wild-type enzyme.","evidence":"X-ray crystallography of substrate/product complexes, NMR, mutant homo/heterodimer activity assays, CA150 Co-IP","pmids":["17293595","17355961","17440703","18805785"],"confidence":"High","gaps":["In vivo substrate still not pinned down","Functional relevance of CA150/proline-rich interactions untested"]},{"year":2007,"claim":"Defined TREX1 as an essential negative regulator of the ISD response that metabolizes reverse-transcribed and replication-derived ssDNA, establishing its homeostatic innate-immune function.","evidence":"Genetic ISD pathway analysis, Trex1⁻/⁻ cells, retroelement DNA accumulation, ER-to-nucleus relocalization after genotoxic stress","pmids":["18724932","18045533"],"confidence":"High","gaps":["Downstream sensor not yet identified","Mechanism of stress-induced relocalization unresolved"]},{"year":2008,"claim":"Resolved the catalytic-impairment mechanism of disease mutants and identified catalytic metal/residue requirements, refining the structural enzymology.","evidence":"X-ray crystallography of apo and mutant TREX1, His124 mutagenesis, cation inhibition structures","pmids":["22071149","18780819"],"confidence":"High","gaps":["Connection of structural defects to cellular phenotype indirect"]},{"year":2010,"claim":"Showed TREX1 degrades cytosolic HIV reverse-transcribed DNA to suppress type I IFN, extending its substrate range to retroviral DNA and revealing the TBK1/STING/IRF3 axis.","evidence":"Trex1⁻/⁻ cells, human T-cell/macrophage RNAi, Co-IP of TREX1 with HIV DNA, IFN induction assays","pmids":["20871604"],"confidence":"High","gaps":["Whether degradation is direct on viral DNA or via accessory factors not fully resolved"]},{"year":2010,"claim":"Established stress-responsive and cytokine-responsive transcriptional control of TREX1 by AP-1, STAT1, and IFN-γ, embedding the enzyme in feedback regulation.","evidence":"Promoter reporters, EMSA, ChIP, c-fos/c-jun and STAT1 null cells","pmids":["20511593","21239708"],"confidence":"High","gaps":["Quantitative contribution of induction to disease protection unmeasured"]},{"year":2011,"claim":"Dissected the dsDNA-degradation mechanism at endonuclease-generated 3' termini and the metal-dependent dominant-inhibition mechanism, explaining dominant autoimmune phenotypes.","evidence":"In vitro plasmid/chromatin dsDNA assays, mutant competition assays","pmids":["21808053","21937424"],"confidence":"High","gaps":["In vivo source of endonuclease-generated termini unspecified"]},{"year":2012,"claim":"Revealed a type-I-IFN-independent arm of TREX1 deficiency involving lysosomal biogenesis, TFEB, and mTORC1, broadening its cellular impact beyond IFN.","evidence":"Trex1⁻/⁻ cells, STING/TBK1/IRF3/IRF7 epistasis, transcriptomics, lysosomal analysis","pmids":["23160154"],"confidence":"High","gaps":["Mechanistic link between DNA clearance and lysosomal/mTORC1 changes unclear"]},{"year":2013,"claim":"Identified C-terminal ubiquitination and ubiquilin-1 binding as determinants of TREX1 subcellular localization, introducing post-translational control of trafficking.","evidence":"Deletion constructs, MS proteomics, Co-IP, co-localization","pmids":["23979357"],"confidence":"High","gaps":["Physiological consequence of ubiquilin-1-directed punctae untested","Ubiquitin ligase unknown"]},{"year":2013,"claim":"Showed that oxidative DNA modification (8-OHG) renders DNA resistant to TREX1, providing a mechanism by which damaged self/pathogen DNA escapes clearance and activates cGAS-STING.","evidence":"In vitro degradation assays with oxidized DNA, cytosolic sensing assays","pmids":["23993650"],"confidence":"High","gaps":["In vivo contribution of 8-OHG resistance to autoimmunity not quantified"]},{"year":2014,"claim":"Placed cGAS as the required sensor downstream of TREX1 loss both in cells and in vivo, defining the genetic backbone of TREX1-deficiency disease.","evidence":"TREX1/cGAS double-knockout cells and mice, ISG and autoantibody readouts","pmids":["24813208","26223655"],"confidence":"High","gaps":["Tissue-specific drivers of inflammation not dissected"]},{"year":2014,"claim":"Defined a trans-acting dimer-interface residue (Arg62) and a PARP1 interaction, refining dimer catalysis and hinting at DNA-damage-response roles.","evidence":"Mutant heterodimer activity assays; MS, Co-IP, domain mapping for PARP1","pmids":["24616097","25278026"],"confidence":"Medium","gaps":["PARP1 stabilization claim is partial/suggestive from a single lab","Functional role of nuclear TREX1-PARP1 interaction unresolved"]},{"year":2015,"claim":"Expanded TREX1 to an exoribonuclease, defined the dsDNA-unwinding mechanism in a knock-in lupus model, and uncovered the nuclease-independent OST-complex function, separating TREX1's two distinct activities.","evidence":"In vitro RNA assays, D18N-dsDNA crystal structure with D18N knock-in mice, OST Co-IP with frameshift mice/patient cells and aclacinomycin rescue","pmids":["25855793","25848017","26320659"],"confidence":"High","gaps":["Physiological RNA substrates of TREX1 in vivo unidentified","How OST interaction integrates with nuclease function unclear"]},{"year":2017,"claim":"Established TREX1 as a cell-cycle-regulated (CDK1/Ser261) and radiation-induced enzyme that restrains tumor immunogenicity and suppresses L1 retrotransposons by a nuclease-independent ORF1p mechanism.","evidence":"MS phosphosite mapping with phosphomimetics, radiation dose-response with cGAS/STING readouts and tumor models, ORF1p Co-IP and L1 retrotransposition assays","pmids":["28297665","28598415","28334850"],"confidence":"Medium","gaps":["L1 ORF1p depletion mechanism (single lab, two methods) needs reciprocal validation","Phosphatase identity at mitotic exit inferred not proven"]},{"year":2018,"claim":"Provided comprehensive structural views of TREX1 on branched DNA substrates showing capping and processive duplex digestion, and linked TREX1 to immunostimulatory exosome DNA cargo.","evidence":"Crystal structures of multiple TREX1-DNA complexes; exosome transfer and DC stimulation assays with TREX1 KD","pmids":["29734329","29907693"],"confidence":"High","gaps":["Exosome study is medium-confidence single-lab; in vivo generality untested"]},{"year":2021,"claim":"Showed that ER tethering directs TREX1 to ruptured micronuclei and NE-rupture sites for DNA resection, that cGAS phase separation locally shields DNA from TREX1, and that nuclear TREX1 can itself drive DNA damage and cancer progression.","evidence":"Micronuclei purification with ER tracking and disease-mutant analysis, in vitro cGAS-DNA phase-separation reconstitution, live imaging of NE rupture in mammary duct models","pmids":["33476576","33606975","34551315"],"confidence":"High","gaps":["How ER membrane gains access to ruptured envelopes mechanistically unresolved","Balance between protective resection and damaging nuclear activity context-dependent"]},{"year":2022,"claim":"Delivered the high-resolution human TREX1 structure with full disease-mutation mapping and assigned new substrate activities (NER sedDNA, 3'-PUA DNA-protein cross-links), broadening TREX1's role in DNA repair processing.","evidence":"Human apo (1.25 Å) and DNA-bound crystal structures; in vitro and cell assays with sedDNA; purified-enzyme DPC repair kinetics","pmids":["35879334","35357486","35349719"],"confidence":"High","gaps":["In vivo importance of sedDNA/DPC processing for genome stability unquantified","Whether these activities feed cGAS signaling untested"]},{"year":2023,"claim":"Defined the structural/dynamic basis for TREX1 RNA discrimination and showed TREX1 clears virus-released cytoplasmic mitochondrial DNA to dampen antiviral sensing.","evidence":"Crystal structures, MD simulations and binding affinities on DNA/RNA junctions; CRISPR fitness screen and KO with mtDNA/cGAS-STING readouts during influenza infection","pmids":["37870446","37652009"],"confidence":"High","gaps":["Generality of mtDNA clearance across other infections untested"]},{"year":2024,"claim":"Established TREX1 as a STAT1-driven negative-feedback brake on STING signaling exploitable for immunotherapy, and showed RVCL frameshift mutants mislocalize to the nucleus to impair HDR while TREX1 broadly limits CRISPR HDR template availability.","evidence":"Cancer-cell KO with in vivo tumor/PD-1 models; multi-organism (human/mouse/Drosophila) RVCL mutant HDR assays; genome-wide CRISPR HDR screen with protected-template rescue","pmids":["38227896","38824133","39134754"],"confidence":"High","gaps":["Therapeutic window of TREX1 inhibition versus autoimmunity risk undefined","How nuclear mislocalization mechanistically blocks HDR not fully resolved"]},{"year":null,"claim":"How TREX1's distinct activities — cytosolic DNA/RNA degradation, ER-tethered micronuclear resection, nuclease-independent OST stabilization, and DNA-repair processing — are coordinated and prioritized in a single cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of how localization, PTMs, and partner interactions partition TREX1 between protective and pathogenic functions","Physiological RNA and DPC substrates in vivo unidentified","Mechanism coupling DNA clearance to lysosomal/mTORC1 program unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[0,1,5,9,15,30,35,36,37]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,9,22,38]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[22,38]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[5,15,23,30,35]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[22,38]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[4,10,24,33]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,10,14,21,34,41]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8,13,20,39]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,13,17,20,25,26,39,40]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[8,19,20,33]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[36,37,41,42]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,23,24,41]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,7]}],"complexes":["SET complex","oligosaccharyltransferase (OST) complex"],"partners":["SET","NME1/NM23-H1","RPN1","UBQLN1","PARP1","L1 ORF1P","CGAS"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NSU2","full_name":"Three-prime repair exonuclease 1","aliases":["3'-5' exonuclease TREX1","Deoxyribonuclease III","DNase III"],"length_aa":314,"mass_kda":33.2,"function":"Major cellular 3'-to-5' DNA exonuclease which digests single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) with mismatched 3' termini (PubMed:10391904, PubMed:10393201, PubMed:17293595). Prevents cell-intrinsic initiation of autoimmunity (PubMed:10391904, PubMed:10393201, PubMed:17293595). Acts by metabolizing DNA fragments from endogenous retroelements, including L1, LTR and SINE elements (PubMed:10391904, PubMed:10393201, PubMed:17293595). Plays a key role in degradation of DNA fragments at cytosolic micronuclei arising from genome instability: its association with the endoplasmic reticulum membrane directs TREX1 to ruptured micronuclei, leading to micronuclear DNA degradation (PubMed:33476576). Micronuclear DNA degradation is required to limit CGAS activation and subsequent inflammation (PubMed:33476576). Unless degraded, these DNA fragments accumulate in the cytosol and activate the cGAS-STING innate immune signaling, leading to the production of type I interferon (PubMed:33476576). Prevents chronic ATM-dependent checkpoint activation, by processing ssDNA polynucleotide species arising from the processing of aberrant DNA replication intermediates (PubMed:18045533). Inefficiently degrades oxidized DNA, such as that generated upon antimicrobial reactive oxygen production or upon absorption of UV light (PubMed:23993650). During GZMA-mediated cell death, contributes to DNA damage in concert with NME1 (PubMed:16818237). NME1 nicks one strand of DNA and TREX1 removes bases from the free 3' end to enhance DNA damage and prevent DNA end reannealing and rapid repair (PubMed:16818237)","subcellular_location":"Nucleus; Cytoplasm, cytosol; Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q9NSU2/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TREX1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TREX1","total_profiled":1310},"omim":[{"mim_id":"613973","title":"CYCLIC GMP-AMP SYNTHASE; CGAS","url":"https://www.omim.org/entry/613973"},{"mim_id":"610448","title":"CHILBLAIN LUPUS 1; CHBL1","url":"https://www.omim.org/entry/610448"},{"mim_id":"609423","title":"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609423"},{"mim_id":"607110","title":"APOLIPOPROTEIN B mRNA-EDITING ENZYME, CATALYTIC POLYPEPTIDE-LIKE 3B; APOBEC3B","url":"https://www.omim.org/entry/607110"},{"mim_id":"606754","title":"SAM DOMAIN- AND HD DOMAIN-CONTAINING PROTEIN 1; SAMHD1","url":"https://www.omim.org/entry/606754"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TREX1"},"hgnc":{"alias_symbol":["DRN3"],"prev_symbol":["AGS1"]},"alphafold":{"accession":"Q9NSU2","domains":[{"cath_id":"3.30.420.10","chopping":"14-229","consensus_level":"high","plddt":94.48,"start":14,"end":229}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NSU2","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NSU2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NSU2-F1-predicted_aligned_error_v6.png","plddt_mean":80.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TREX1","jax_strain_url":"https://www.jax.org/strain/search?query=TREX1"},"sequence":{"accession":"Q9NSU2","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NSU2.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NSU2/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NSU2"}},"corpus_meta":[{"pmid":"28598415","id":"PMC_28598415","title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28598415","citation_count":1467,"is_preprint":false},{"pmid":"18724932","id":"PMC_18724932","title":"Trex1 prevents cell-intrinsic initiation of autoimmunity.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18724932","citation_count":1061,"is_preprint":false},{"pmid":"16845398","id":"PMC_16845398","title":"Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus.","date":"2006","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16845398","citation_count":749,"is_preprint":false},{"pmid":"17660818","id":"PMC_17660818","title":"Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17660818","citation_count":565,"is_preprint":false},{"pmid":"18045533","id":"PMC_18045533","title":"Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18045533","citation_count":481,"is_preprint":false},{"pmid":"20871604","id":"PMC_20871604","title":"The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1.","date":"2010","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20871604","citation_count":436,"is_preprint":false},{"pmid":"23993650","id":"PMC_23993650","title":"Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing.","date":"2013","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23993650","citation_count":394,"is_preprint":false},{"pmid":"24183309","id":"PMC_24183309","title":"Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.","date":"2013","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24183309","citation_count":371,"is_preprint":false},{"pmid":"15254239","id":"PMC_15254239","title":"Gene-targeted mice lacking the Trex1 (DNase III) 3'-->5' DNA exonuclease develop inflammatory myocarditis.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15254239","citation_count":328,"is_preprint":false},{"pmid":"26223655","id":"PMC_26223655","title":"Cutting Edge: cGAS Is Required for Lethal Autoimmune Disease in the Trex1-Deficient Mouse Model of Aicardi-Goutières Syndrome.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26223655","citation_count":324,"is_preprint":false},{"pmid":"17357087","id":"PMC_17357087","title":"Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17357087","citation_count":308,"is_preprint":false},{"pmid":"29907693","id":"PMC_29907693","title":"Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs.","date":"2018","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/29907693","citation_count":307,"is_preprint":false},{"pmid":"28803918","id":"PMC_28803918","title":"Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation.","date":"2017","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/28803918","citation_count":262,"is_preprint":false},{"pmid":"10391904","id":"PMC_10391904","title":"Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3'-->5' exonucleases.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10391904","citation_count":242,"is_preprint":false},{"pmid":"21270825","id":"PMC_21270825","title":"Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort.","date":"2011","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21270825","citation_count":220,"is_preprint":false},{"pmid":"16818237","id":"PMC_16818237","title":"The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16818237","citation_count":219,"is_preprint":false},{"pmid":"24813208","id":"PMC_24813208","title":"TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24813208","citation_count":216,"is_preprint":false},{"pmid":"34551315","id":"PMC_34551315","title":"Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/34551315","citation_count":209,"is_preprint":false},{"pmid":"28279982","id":"PMC_28279982","title":"A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1.","date":"2017","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/28279982","citation_count":191,"is_preprint":false},{"pmid":"17440703","id":"PMC_17440703","title":"A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus.","date":"2007","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17440703","citation_count":180,"is_preprint":false},{"pmid":"33606975","id":"PMC_33606975","title":"cGAS phase separation inhibits TREX1-mediated DNA degradation and enhances cytosolic DNA sensing.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33606975","citation_count":172,"is_preprint":false},{"pmid":"25731743","id":"PMC_25731743","title":"Human disease phenotypes associated with mutations in TREX1.","date":"2015","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25731743","citation_count":171,"is_preprint":false},{"pmid":"33476576","id":"PMC_33476576","title":"ER-directed TREX1 limits cGAS activation at micronuclei.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33476576","citation_count":166,"is_preprint":false},{"pmid":"25848017","id":"PMC_25848017","title":"Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25848017","citation_count":151,"is_preprint":false},{"pmid":"11279105","id":"PMC_11279105","title":"Excision of 3' termini by the Trex1 and TREX2 3'-->5' exonucleases. Characterization of the recombinant proteins.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11279105","citation_count":139,"is_preprint":false},{"pmid":"23160154","id":"PMC_23160154","title":"Trex1 regulates lysosomal biogenesis and interferon-independent activation of antiviral genes.","date":"2012","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23160154","citation_count":127,"is_preprint":false},{"pmid":"18805785","id":"PMC_18805785","title":"The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18805785","citation_count":115,"is_preprint":false},{"pmid":"29781188","id":"PMC_29781188","title":"Inhibition of Cyclic GMP-AMP Synthase Using a Novel Antimalarial Drug Derivative in Trex1-Deficient Mice.","date":"2018","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/29781188","citation_count":115,"is_preprint":false},{"pmid":"17293595","id":"PMC_17293595","title":"The crystal structure of TREX1 explains the 3' nucleotide specificity and reveals a polyproline II helix for protein partnering.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17293595","citation_count":103,"is_preprint":false},{"pmid":"18583934","id":"PMC_18583934","title":"New roles for the major human 3'-5' exonuclease TREX1 in human disease.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18583934","citation_count":100,"is_preprint":false},{"pmid":"28475463","id":"PMC_28475463","title":"Immune Diseases Associated with TREX1 and STING Dysfunction.","date":"2017","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/28475463","citation_count":92,"is_preprint":false},{"pmid":"26320659","id":"PMC_26320659","title":"Cytosolic Nuclease TREX1 Regulates Oligosaccharyltransferase Activity Independent of Nuclease Activity to Suppress Immune Activation.","date":"2015","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/26320659","citation_count":90,"is_preprint":false},{"pmid":"38227896","id":"PMC_38227896","title":"TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity.","date":"2024","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38227896","citation_count":86,"is_preprint":false},{"pmid":"30872080","id":"PMC_30872080","title":"cGAS activation causes lupus-like autoimmune disorders in a TREX1 mutant mouse model.","date":"2019","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/30872080","citation_count":78,"is_preprint":false},{"pmid":"27511730","id":"PMC_27511730","title":"Loss of Trex1 in Dendritic Cells Is Sufficient To Trigger Systemic Autoimmunity.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27511730","citation_count":73,"is_preprint":false},{"pmid":"28334850","id":"PMC_28334850","title":"Aicardi-Goutières syndrome protein TREX1 suppresses L1 and maintains genome integrity through exonuclease-independent ORF1p depletion.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28334850","citation_count":72,"is_preprint":false},{"pmid":"30673078","id":"PMC_30673078","title":"Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.","date":"2019","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30673078","citation_count":68,"is_preprint":false},{"pmid":"21808053","id":"PMC_21808053","title":"Dominant mutation of the TREX1 exonuclease gene in lupus and Aicardi-Goutieres syndrome.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21808053","citation_count":65,"is_preprint":false},{"pmid":"11278605","id":"PMC_11278605","title":"Structure and expression of the TREX1 and TREX2 3' --> 5' exonuclease genes.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278605","citation_count":64,"is_preprint":false},{"pmid":"20511593","id":"PMC_20511593","title":"Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo(a)pyrene-induced DNA damage.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/20511593","citation_count":60,"is_preprint":false},{"pmid":"25138095","id":"PMC_25138095","title":"Identification of a pathogenic variant in TREX1 in early-onset cerebral systemic lupus erythematosus by Whole-exome sequencing.","date":"2014","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/25138095","citation_count":59,"is_preprint":false},{"pmid":"33868310","id":"PMC_33868310","title":"TREX1 as a Novel Immunotherapeutic Target.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33868310","citation_count":56,"is_preprint":false},{"pmid":"19442247","id":"PMC_19442247","title":"Biochemical properties of mammalian TREX1 and its association with DNA replication and inherited inflammatory disease.","date":"2009","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/19442247","citation_count":50,"is_preprint":false},{"pmid":"35879334","id":"PMC_35879334","title":"Structural basis of human TREX1 DNA degradation and autoimmune disease.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35879334","citation_count":49,"is_preprint":false},{"pmid":"27886180","id":"PMC_27886180","title":"MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27886180","citation_count":49,"is_preprint":false},{"pmid":"25278026","id":"PMC_25278026","title":"The 3'-5' DNA exonuclease TREX1 directly interacts with poly(ADP-ribose) polymerase-1 (PARP1) during the DNA damage response.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25278026","citation_count":49,"is_preprint":false},{"pmid":"32615442","id":"PMC_32615442","title":"TREX1 - Apex predator of cytosolic DNA metabolism.","date":"2020","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/32615442","citation_count":48,"is_preprint":false},{"pmid":"17355961","id":"PMC_17355961","title":"Structure of the dimeric exonuclease TREX1 in complex with DNA displays a proline-rich binding site for WW Domains.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17355961","citation_count":48,"is_preprint":false},{"pmid":"24218451","id":"PMC_24218451","title":"The exonuclease Trex1 restrains macrophage proinflammatory activation.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24218451","citation_count":47,"is_preprint":false},{"pmid":"25213617","id":"PMC_25213617","title":"TREX1 C-terminal frameshift mutations in the systemic variant of retinal vasculopathy with cerebral leukodystrophy.","date":"2014","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/25213617","citation_count":47,"is_preprint":false},{"pmid":"37652009","id":"PMC_37652009","title":"Pathogen-driven CRISPR screens identify TREX1 as a regulator of DNA self-sensing during influenza virus infection.","date":"2023","source":"Cell host & microbe","url":"https://pubmed.ncbi.nlm.nih.gov/37652009","citation_count":42,"is_preprint":false},{"pmid":"21937424","id":"PMC_21937424","title":"The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21937424","citation_count":42,"is_preprint":false},{"pmid":"38489753","id":"PMC_38489753","title":"The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity.","date":"2024","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/38489753","citation_count":39,"is_preprint":false},{"pmid":"25855793","id":"PMC_25855793","title":"Human DNA Exonuclease TREX1 Is Also an Exoribonuclease That Acts on Single-stranded RNA.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25855793","citation_count":39,"is_preprint":false},{"pmid":"23979357","id":"PMC_23979357","title":"The TREX1 C-terminal region controls cellular localization through ubiquitination.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23979357","citation_count":39,"is_preprint":false},{"pmid":"29734329","id":"PMC_29734329","title":"Structural basis for overhang excision and terminal unwinding of DNA duplexes by TREX1.","date":"2018","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/29734329","citation_count":38,"is_preprint":false},{"pmid":"20799324","id":"PMC_20799324","title":"A de novo p.Asp18Asn mutation in TREX1 in a patient with Aicardi-Goutières syndrome.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20799324","citation_count":38,"is_preprint":false},{"pmid":"19617005","id":"PMC_19617005","title":"TREX1 acts in degrading damaged DNA from drug-treated tumor cells.","date":"2009","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/19617005","citation_count":35,"is_preprint":false},{"pmid":"28835460","id":"PMC_28835460","title":"Lack of Trex1 Causes Systemic Autoimmunity despite the Presence of Antiretroviral Drugs.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28835460","citation_count":35,"is_preprint":false},{"pmid":"29769349","id":"PMC_29769349","title":"HIV-1 Activation of Innate Immunity Depends Strongly on the Intracellular Level of TREX1 and Sensing of Incomplete Reverse Transcription Products.","date":"2018","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/29769349","citation_count":35,"is_preprint":false},{"pmid":"38408184","id":"PMC_38408184","title":"Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN.","date":"2024","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/38408184","citation_count":33,"is_preprint":false},{"pmid":"24224166","id":"PMC_24224166","title":"Rare variants in the TREX1 gene and susceptibility to autoimmune diseases.","date":"2013","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24224166","citation_count":31,"is_preprint":false},{"pmid":"28325644","id":"PMC_28325644","title":"DNase-active TREX1 frame-shift mutants induce serologic autoimmunity in mice.","date":"2017","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/28325644","citation_count":30,"is_preprint":false},{"pmid":"23578789","id":"PMC_23578789","title":"Human three prime exonuclease TREX1 is induced by genotoxic stress and involved in protection of glioma and melanoma cells to anticancer drugs.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23578789","citation_count":29,"is_preprint":false},{"pmid":"24300241","id":"PMC_24300241","title":"A nationwide survey of Aicardi-Goutières syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study.","date":"2013","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24300241","citation_count":29,"is_preprint":false},{"pmid":"35349719","id":"PMC_35349719","title":"Human TDP1, APE1 and TREX1 repair 3'-DNA-peptide/protein cross-links arising from abasic sites in vitro.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/35349719","citation_count":28,"is_preprint":false},{"pmid":"37416470","id":"PMC_37416470","title":"Suppression of TREX1 deficiency-induced cellular senescence and interferonopathies by inhibition of DNA damage response.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/37416470","citation_count":27,"is_preprint":false},{"pmid":"26150267","id":"PMC_26150267","title":"Typing TREX1 gene in patients with systemic lupus erythematosus.","date":"2015","source":"Reumatismo","url":"https://pubmed.ncbi.nlm.nih.gov/26150267","citation_count":27,"is_preprint":false},{"pmid":"23602593","id":"PMC_23602593","title":"A homozygous NOTCH3 mutation p.R544C and a heterozygous TREX1 variant p.C99MfsX3 in a family with hereditary small vessel disease of the brain.","date":"2013","source":"Journal of the Chinese Medical Association : JCMA","url":"https://pubmed.ncbi.nlm.nih.gov/23602593","citation_count":27,"is_preprint":false},{"pmid":"22071149","id":"PMC_22071149","title":"Defects in DNA degradation revealed in crystal structures of TREX1 exonuclease mutations linked to autoimmune disease.","date":"2011","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/22071149","citation_count":27,"is_preprint":false},{"pmid":"31475890","id":"PMC_31475890","title":"TREX1 As a Potential Therapeutic Target for Autoimmune and Inflammatory Diseases.","date":"2019","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/31475890","citation_count":26,"is_preprint":false},{"pmid":"24817865","id":"PMC_24817865","title":"Safeguard against DNA sensing: the role of TREX1 in HIV-1 infection and autoimmune diseases.","date":"2014","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/24817865","citation_count":26,"is_preprint":false},{"pmid":"35357486","id":"PMC_35357486","title":"TREX1 degrades the 3' end of the small DNA oligonucleotide products of nucleotide excision repair in human cells.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/35357486","citation_count":24,"is_preprint":false},{"pmid":"31826941","id":"PMC_31826941","title":"T Cells Produce IFN-α in the TREX1 D18N Model of Lupus-like Autoimmunity.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31826941","citation_count":24,"is_preprint":false},{"pmid":"35489653","id":"PMC_35489653","title":"Cytoplasmic DNA in cancer cells: Several pathways that potentially limit DNase2 and TREX1 activities.","date":"2022","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/35489653","citation_count":23,"is_preprint":false},{"pmid":"34400195","id":"PMC_34400195","title":"Photosensitivity and cGAS-Dependent IFN-1 Activation in Patients with Lupus and TREX1 Deficiency.","date":"2021","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34400195","citation_count":23,"is_preprint":false},{"pmid":"38824133","id":"PMC_38824133","title":"Inherited C-terminal TREX1 variants disrupt homology-directed repair to cause senescence and DNA damage phenotypes in Drosophila, mice, and humans.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38824133","citation_count":22,"is_preprint":false},{"pmid":"28297665","id":"PMC_28297665","title":"Mitotic Phosphorylation of TREX1 C Terminus Disrupts TREX1 Regulation of the Oligosaccharyltransferase Complex.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28297665","citation_count":22,"is_preprint":false},{"pmid":"30674977","id":"PMC_30674977","title":"Three Prime Repair Exonuclease 1 (TREX1) expression correlates with cervical cancer cells growth in vitro and disease progression in vivo.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30674977","citation_count":22,"is_preprint":false},{"pmid":"21239708","id":"PMC_21239708","title":"Characterization of Trex1 induction by IFN-γ in murine macrophages.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21239708","citation_count":22,"is_preprint":false},{"pmid":"18780819","id":"PMC_18780819","title":"Structural and biochemical studies of TREX1 inhibition by metals. Identification of a new active histidine conserved in DEDDh exonucleases.","date":"2008","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/18780819","citation_count":22,"is_preprint":false},{"pmid":"38926338","id":"PMC_38926338","title":"MRE11 and TREX1 control senescence by coordinating replication stress and interferon signaling.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38926338","citation_count":21,"is_preprint":false},{"pmid":"32565148","id":"PMC_32565148","title":"Celastrol ameliorates autoimmune disorders in Trex1-deficient mice.","date":"2020","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32565148","citation_count":21,"is_preprint":false},{"pmid":"28625463","id":"PMC_28625463","title":"TREX1 Cuts Down on Cancer Immunogenicity.","date":"2017","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/28625463","citation_count":21,"is_preprint":false},{"pmid":"18406216","id":"PMC_18406216","title":"TREX1 DNA exonuclease deficiency, accumulation of single stranded DNA and complex human genetic disorders.","date":"2008","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/18406216","citation_count":21,"is_preprint":false},{"pmid":"24598055","id":"PMC_24598055","title":"TLR ligands up-regulate Trex1 expression in murine conventional dendritic cells through type I Interferon and NF-κB-dependent signaling pathways.","date":"2014","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/24598055","citation_count":21,"is_preprint":false},{"pmid":"39177280","id":"PMC_39177280","title":"Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer.","date":"2024","source":"Cancer research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39177280","citation_count":20,"is_preprint":false},{"pmid":"31326279","id":"PMC_31326279","title":"TREX1 variants in Sjogren's syndrome related lymphomagenesis.","date":"2019","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/31326279","citation_count":20,"is_preprint":false},{"pmid":"36745566","id":"PMC_36745566","title":"TREX1 cytosolic DNA degradation correlates with autoimmune disease and cancer immunity.","date":"2023","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36745566","citation_count":20,"is_preprint":false},{"pmid":"39134754","id":"PMC_39134754","title":"Removal of TREX1 activity enhances CRISPR-Cas9-mediated homologous recombination.","date":"2024","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39134754","citation_count":19,"is_preprint":false},{"pmid":"33407657","id":"PMC_33407657","title":"Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib.","date":"2021","source":"Pediatric rheumatology online journal","url":"https://pubmed.ncbi.nlm.nih.gov/33407657","citation_count":19,"is_preprint":false},{"pmid":"35468328","id":"PMC_35468328","title":"TREX1 plays multiple roles in human diseases.","date":"2022","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35468328","citation_count":18,"is_preprint":false},{"pmid":"29941221","id":"PMC_29941221","title":"TREX1 Mutation Causing Autosomal Dominant Thrombotic Microangiopathy and CKD-A Novel Presentation.","date":"2018","source":"American journal of kidney diseases : the official journal of the National Kidney Foundation","url":"https://pubmed.ncbi.nlm.nih.gov/29941221","citation_count":18,"is_preprint":false},{"pmid":"30422000","id":"PMC_30422000","title":"TREX1 D18N mice fail to process erythroblast DNA resulting in inflammation and dysfunctional erythropoiesis.","date":"2018","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/30422000","citation_count":18,"is_preprint":false},{"pmid":"37870446","id":"PMC_37870446","title":"Molecular insight into the specific enzymatic properties of TREX1 revealing the diverse functions in processing RNA and DNA/RNA hybrids.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/37870446","citation_count":17,"is_preprint":false},{"pmid":"31455522","id":"PMC_31455522","title":"Measuring TREX1 and TREX2 exonuclease activities.","date":"2019","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/31455522","citation_count":16,"is_preprint":false},{"pmid":"38129659","id":"PMC_38129659","title":"TREX1 is required for microglial cholesterol homeostasis and oligodendrocyte terminal differentiation in human neural assembloids.","date":"2023","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/38129659","citation_count":16,"is_preprint":false},{"pmid":"18092167","id":"PMC_18092167","title":"TREX1 polymorphisms associated with autoantibodies in patients with systemic lupus erythematosus.","date":"2007","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/18092167","citation_count":16,"is_preprint":false},{"pmid":"30062819","id":"PMC_30062819","title":"TREX1 is expressed by microglia in normal human brain and increases in regions affected by ischemia.","date":"2018","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30062819","citation_count":16,"is_preprint":false},{"pmid":"24616097","id":"PMC_24616097","title":"The Arg-62 residues of the TREX1 exonuclease act across the dimer interface contributing to catalysis in the opposing protomers.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24616097","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47319,"output_tokens":11764,"usd":0.159209,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":23043,"output_tokens":6846,"usd":0.143182,"stage2_stop_reason":"end_turn"},"total_usd":0.302391,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"TREX1 encodes a 304-amino acid protein with three conserved motifs generating the exonuclease active site, most closely related to proofreading exonucleases of bacterial replicative DNA polymerases. Recombinant TREX1 expressed in E. coli is an active 3'→5' DNA exonuclease with greatest activity on partial duplex DNA containing 3' mismatched nucleotides; no activity was detected on single-stranded RNA or RNA-DNA partial duplexes.\",\n      \"method\": \"Recombinant protein expression in E. coli, in vitro exonuclease activity assays with ssDNA, partial duplex, and mispaired oligonucleotide substrates\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro with purified recombinant protein, multiple substrate types tested, foundational biochemical characterization\",\n      \"pmids\": [\"10391904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TREX1 (mouse) exists as a homodimer with robust 3'→5' exonuclease activity. Steady-state kinetics on ssDNA oligonucleotides yielded kcat ~22 s⁻¹ and KM ~19 nM for mouse Trex1. Competition assays with heparin and partial duplex DNA substrates established substrate structure preferences for 3' nucleotide excision.\",\n      \"method\": \"Recombinant protein expression and purification from E. coli, steady-state kinetic analysis, heparin competition assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro with purified protein, rigorous kinetic characterization with multiple methods\",\n      \"pmids\": [\"11279105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Gene-targeted Trex1⁻/⁻ mice are viable but develop inflammatory myocarditis leading to cardiomyopathy and circulatory failure, establishing that TREX1 loss-of-function in vivo causes inflammatory disease rather than increased mutation frequency or cancer.\",\n      \"method\": \"Gene targeting (knockout mice), histopathology, survival analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic KO with defined inflammatory phenotype, replicated in subsequent studies\",\n      \"pmids\": [\"15254239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TREX1 is the major mammalian 3'→5' DNA exonuclease encoded by AGS1; AGS-causing mutations abrogate TREX1 enzyme activity, and similar loss-of-function in Trex1⁻/⁻ mice leads to an inflammatory phenotype, implicating TREX1 in processing or clearing anomalous DNA structures to prevent innate immune triggering.\",\n      \"method\": \"Mutational analysis, exonuclease activity assays of patient-derived mutations, Trex1⁻/⁻ mouse model\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — enzyme activity assays on disease-associated mutants combined with genetic mouse model, replicated across labs\",\n      \"pmids\": [\"16845398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TREX1 (but not TREX2) is a component of the endoplasmic reticulum-associated SET complex. TREX1 binds SET, colocalizes and translocates with the SET complex to the nucleus during granzyme A-mediated apoptosis, where it works in concert with NM23-H1 to degrade genomic DNA: after NM23-H1 nicks DNA, TREX1 removes nucleotides from the nicked 3' end. Silencing TREX1 inhibits DNA damage and cell death in response to perforin/granzyme A but not perforin/granzyme B.\",\n      \"method\": \"Co-immunoprecipitation, colocalization by immunofluorescence, siRNA knockdown, cell death assays with perforin/granzyme A treatment\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, functional siRNA knockdown with specific phenotypic readout, multiple orthogonal methods\",\n      \"pmids\": [\"16818237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Crystal structure of dimeric mouse TREX1 in substrate and product complexes with ssDNA and deoxyadenosine monophosphate reveals specific active-site interactions with the 3'-terminal nucleotide, providing molecular basis for specificity. Three AGS-associated TREX1 mutants show 4–35,000-fold reduced enzyme activity. The structure reveals an 8-amino acid polyproline II helix on the surface suggesting a mechanism for interactions with other protein complexes.\",\n      \"method\": \"X-ray crystallography, site-directed mutagenesis, in vitro exonuclease activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure at substrate/product complex level combined with mutagenesis and activity assays in one rigorous study\",\n      \"pmids\": [\"17293595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Crystal structures of dimeric murine TREX1 complexed with a nucleotide product and ssDNA substrate reveal sequence preferences for certain DNA motifs (GAG, ACA, CTGC). A conserved proline-rich region (PPPVPRPP) on the TREX1 surface interacts with WW2 domain of transcription elongation factor CA150, confirmed by NMR titration and co-immunoprecipitation with full-length TREX1. Nuclear localization of TREX1 requires loss of a C-terminal segment (leucine-rich repeat 3).\",\n      \"method\": \"X-ray crystallography, NMR titration, co-immunoprecipitation, confocal microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with NMR and Co-IP, multiple orthogonal methods in one study\",\n      \"pmids\": [\"17355961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TREX1 acts in concert with the SET complex in granzyme A-mediated apoptosis. A heterozygous D18N mutation in TREX1 renders recombinant mutant TREX1 homodimers enzymatically inactive; wild-type/D18N heterodimers retain residual activity. Lymphoblastoid cells with D18N are significantly less sensitive to granzyme A-mediated cell death.\",\n      \"method\": \"Recombinant protein preparation, in vitro exonuclease activity assays, granzyme A cell death assays in patient-derived lymphoblastoid cells\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — recombinant enzyme biochemistry plus cell-based functional assay, single lab but two orthogonal methods\",\n      \"pmids\": [\"17440703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TREX1 is an essential negative regulator of the IFN-stimulatory DNA (ISD) response. In Trex1-deficient cells, single-stranded DNA derived from endogenous retroelements accumulates. TREX1 can metabolize reverse-transcribed DNA, preventing chronic activation of innate immune signaling. Genetic pathway analysis links Trex1 deficiency to lethal autoimmunity through the ISD pathway.\",\n      \"method\": \"Genetic screen, Trex1⁻/⁻ mouse cells, ISD pathway reporter assays, DNA accumulation analysis, epistasis via Trex1 KO rescue experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including genetic pathway placement, cell-intrinsic functional assays, replicated across labs\",\n      \"pmids\": [\"18724932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Dominant mutations in TREX1 (D200N and D18N) associated with autoimmune disease exhibit completely deficient dsDNA degradation activity while retaining partial ssDNA degradation activity. The dominant mutant heterodimers (WT/D200N and WT/D18N) inhibit the dsDNA degradation activity of WT TREX1 enzyme, explaining the dominant phenotype. The recessive R114H homodimer has dysfunctional dsDNA and ssDNA activities but does not inhibit WT enzyme.\",\n      \"method\": \"In vitro exonuclease activity assays with nicked dsDNA and ssDNA substrates using recombinant homo- and heterodimers\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro biochemical reconstitution with disease-relevant mutant proteins, single lab but multiple substrate types\",\n      \"pmids\": [\"18805785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Trex1, ordinarily associated with the endoplasmic reticulum, relocalizes to the S-phase nucleus after gamma irradiation or hydroxyurea treatment. Trex1-deficient cells show chronic ATM-dependent checkpoint activation even without exogenous stress, correlated with persistent ssDNA produced in S phase accumulating in the ER. Trex1 degrades ssDNA arising from aberrant replication intermediates to prevent chronic checkpoint signaling.\",\n      \"method\": \"Immunofluorescence/subcellular fractionation, gamma irradiation, hydroxyurea treatment, ATM inhibition, Trex1⁻/⁻ cells\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiments with functional consequence, genetic KO with defined molecular phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"18045533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"X-ray crystal structures of TREX1 apoprotein, dominant AGS/FCL mutants (D200H, D200N, D18N) and recessive mutant (V201D) reveal mechanism of catalytic impairment: D200H and D200N lose coordination of one active-site metal and the catalytic histidine (H195) is trapped in a non-catalytic conformation; D18N and V201D bind both metals but with inter-metal distances non-optimal for catalysis. All mutants show reduced mobility of catalytic histidine.\",\n      \"method\": \"X-ray crystallography of multiple mutant TREX1 proteins\",\n      \"journal\": \"DNA repair\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures of multiple disease mutants providing mechanistic insight, single lab but comprehensive structural analysis\",\n      \"pmids\": [\"22071149\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Lithium and sodium cations inhibit TREX1 exonuclease activity by competing with catalytic magnesium/manganese for the two metal-binding sites, inducing subtle active-site rearrangements. X-ray structures with Li⁺ and Na⁺ in complex with a nucleotide product explain this inhibition mechanism. Mutagenesis of His124 (highly conserved in DEDDh family) confirmed its requirement for TREX1 activity, identifying it as a catalytic residue.\",\n      \"method\": \"X-ray crystallography at 2.1 Å and 2.3 Å, in vitro exonuclease activity assays, site-directed mutagenesis of His124\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures combined with mutagenesis and activity assays, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"18780819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The cytosolic exonuclease TREX1 suppresses interferon triggered by HIV-1 infection. TREX1 binds cytosolic HIV DNA and degrades excess HIV DNA that would otherwise activate type I interferon via a TBK1/STING/IRF3-dependent pathway. In Trex1⁻/⁻ mouse cells and TREX1-knockdown human CD4⁺ T cells and macrophages, cytosolic HIV DNA accumulates and HIV infection induces type I interferon that inhibits HIV replication.\",\n      \"method\": \"Trex1⁻/⁻ mouse cells, siRNA knockdown in human T cells/macrophages, co-immunoprecipitation of TREX1 with HIV DNA, interferon induction assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional assays in multiple cell types (mouse KO + human RNAi), Co-IP of TREX1 with HIV DNA, pathway dissection via TBK1/STING/IRF3\",\n      \"pmids\": [\"20871604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TREX1 expression is induced by genotoxic stress (UV light, benzo(a)pyrene, hydrogen peroxide) through an AP-1-dependent transcriptional mechanism. The mouse and human trex1 promoters contain AP-1 binding sites recognized by c-Fos and c-Jun; mutational inactivation of the AP-1 site abolishes induction. Upon genotoxic stress, TREX1 also translocates to the nucleus. TREX1-deficient cells show reduced recovery from UV/benzo(a)pyrene-induced replication inhibition.\",\n      \"method\": \"RT-PCR, promoter reporter assays, EMSA, c-fos/c-jun null cells, siRNA knockdown, immunofluorescence localization\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (reporter assays, EMSA, KO cells, localization), single lab\",\n      \"pmids\": [\"20511593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TREX1 degrades plasmid and chromatin dsDNA by locating endonuclease-generated 3' termini. Dominant TREX1 mutants (D18N, D200N, D200H) retain intact DNA binding but have dysfunctional active-site chemistry; competition assays demonstrate that the dominant mutants block access of WT TREX1 to DNA 3' termini through metal-dependent ssDNA binding in catalytically inactive active sites. Residues Arg-174 and Lys-175 act with Arg-128 to facilitate dsDNA melting for ssDNA loading.\",\n      \"method\": \"In vitro exonuclease assays with plasmid and chromatin dsDNA, competition assays with dominant mutant and WT TREX1 proteins\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous biochemical reconstitution with multiple substrate types and mutant proteins, mechanistic dissection of dominant inhibition\",\n      \"pmids\": [\"21808053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TREX1 R114H is a common AGS mutation; the R114H/R114H homodimer has 23-fold reduced ssDNA exonuclease activity. Compound heterodimers R114H/D201ins and R114H/A124ins exhibit 10-fold higher activity than the R114H homodimer, because Arg-114 residues from D201ins and A124ins protomers contribute to catalysis in the opposing R114H protomer across the dimer interface.\",\n      \"method\": \"Recombinant preparation of homo- and heterodimers, ssDNA and dsDNA exonuclease activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with disease-relevant compound heterodimers, mechanistic dissection of dimer interface contributions\",\n      \"pmids\": [\"21937424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Trex1 regulates lysosomal biogenesis and activates a subset of interferon-stimulated genes (ISGs/antiviral genes) independently of type I interferon. This interferon-independent activation in Trex1-deficient cells requires STING, TBK1, IRF3, and IRF7. Trex1-deficient cells also have an expanded lysosomal compartment, altered subcellular localization of TFEB, and diminished mTORC1 activity.\",\n      \"method\": \"Trex1⁻/⁻ mouse cells, STING/TBK1/IRF3/IRF7 genetic epistasis, transcriptomic profiling, lysosomal compartment analysis\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with multiple pathway components, multiple orthogonal cellular readouts, single lab\",\n      \"pmids\": [\"23160154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TREX1 C-terminal region controls cellular localization through ubiquitination. A highly conserved sequence in the CTR is required for ubiquitination at multiple lysine residues through a non-canonical ubiquitin linkage. Ubiquilin 1 was identified by proteomics as a TREX1 CTR-interacting protein (confirmed in vitro and in vivo), and ubiquilin 1 localizes TREX1 to cytosolic punctate structures dependent on the TREX1 CTR and catalytic core lysines. Disease-causing catalytically competent TREX1 mutants show differential ubiquitination and altered ubiquilin 1 co-localization.\",\n      \"method\": \"Deletion construct transfection, mass spectrometry proteomics, co-immunoprecipitation, in vitro binding assay, cotransfection co-localization\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic identification plus Co-IP validation, functional localization experiments with multiple constructs, single lab\",\n      \"pmids\": [\"23979357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Oxidized DNA containing 8-hydroxyguanosine (8-OHG) is resistant to TREX1-mediated degradation. This resistance potentiates cGAS/STING-dependent cytosolic immune recognition, as oxidative modifications reduce TREX1's ability to degrade the DNA. 8-OHG arises in pathogen DNA during lysosomal ROS exposure and in NET DNA during oxidative burst.\",\n      \"method\": \"In vitro TREX1 degradation assays with oxidized vs. unmodified DNA, cytosolic DNA sensing assays, cell-based immune activation experiments\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct in vitro biochemical assay of TREX1 activity on oxidized substrate combined with cellular immune sensing assays\",\n      \"pmids\": [\"23993650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TREX1 deficiency triggers cell-autonomous innate immune activation that is completely dependent on cGAS. Knockout of cGAS in TREX1-deficient cells abrogates spontaneous induction of interferon-stimulated genes, placing cGAS upstream of the type I IFN response in TREX1-deficient settings.\",\n      \"method\": \"TREX1/cGAS double-knockout cells, ISG expression assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean double-KO genetic epistasis placing cGAS as required sensor, replicated by subsequent independent work\",\n      \"pmids\": [\"24813208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TREX1 directly interacts with PARP1 via PARP1's N-terminal zinc finger domains. This interaction occurs after nuclear translocation of TREX1 in response to DNA damage. TREX1 may contribute to stabilization of PARP1 levels and its activity during the DNA damage response.\",\n      \"method\": \"Mass spectrometry, co-immunoprecipitation assays, in vivo overexpression, domain mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP confirmed by MS, domain mapping, but functional claims (stabilization) are partial/suggestive, single lab\",\n      \"pmids\": [\"25278026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TREX1 is also an exoribonuclease that degrades single-stranded RNA but not double-stranded RNA. The AGS disease mutant TREX1-D200N is defective in RNA degradation. TREX1 activity is inhibited by stretches of pyrimidine residues; TREX1 is active on native tRNA substrates. The substrate-binding site is open enough to accommodate the 2'-OH of RNA.\",\n      \"method\": \"In vitro exoribonuclease assays with purified TREX1, kinetic measurements, mutant protein analysis, structural analysis of published crystal structures\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro biochemical reconstitution with purified protein and multiple RNA substrates, kinetics, disease mutant analysis\",\n      \"pmids\": [\"25855793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Crystal structure of TREX1 D18N in complex with dsDNA reveals a novel DNA-unwinding mechanism where TREX1 uses specific residues to separate polynucleotide strands for ssDNA loading into the active site. TREX1 D18N has dysfunctional dsDNA-degrading activity. TREX1 D18N knock-in mice develop systemic lupus-like inflammation with autoantibodies to dsDNA and immune complex deposition, demonstrating that dysfunctional dsDNA degradation alone is sufficient to cause lupus-like disease.\",\n      \"method\": \"X-ray crystallography of TREX1 D18N-dsDNA complex, knock-in mouse model, immunohistochemistry, autoantibody assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with mechanistic insight combined with knock-in mouse model with defined disease phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"25848017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TREX1 C terminus suppresses immune activation independently of nuclease activity by interacting with the ER oligosaccharyltransferase (OST) complex and stabilizing its catalytic integrity. C-terminal frameshift mutations (as in RVCL) dysregulate the OST complex leading to free glycan release from dolichol carriers and immune activation. OST inhibition with aclacinomycin corrects glycan and immune defects in TREX1 frameshift mutant cells and mice.\",\n      \"method\": \"Co-immunoprecipitation of TREX1 with OST complex, glycan analysis, TREX1 KO and frameshift knock-in mice, patient lymphoblasts, aclacinomycin pharmacological rescue\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP of protein complex, multiple genetic models (KO + knock-in mice + patient cells), pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"26320659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"cGAS is required for lethal autoimmune disease in Trex1⁻/⁻ mice. Trex1⁻/⁻ cGAS⁻/⁻ double knockout mice are completely protected from lethality, show dramatically reduced tissue inflammation, and fail to develop autoantibodies, placing cGAS as a key driver of Trex1-deficiency-associated autoimmune disease.\",\n      \"method\": \"Double-knockout mouse genetics, histopathology, survival analysis, autoantibody measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean double-KO genetic epistasis in vivo with multiple disease readouts, replicated independently\",\n      \"pmids\": [\"26223655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"DNA exonuclease TREX1 is induced by radiation doses above 12–18 Gy in cancer cells and attenuates immunogenicity by degrading cytosolic double-stranded DNA that accumulates upon radiation. Cytosolic DNA stimulates IFN-β secretion via cGAS and STING activation. At doses that do not induce TREX1, repeated irradiation amplifies IFN-β production, drives BATF3-dependent DC recruitment and CD8⁺ T cell priming for abscopal tumor rejection.\",\n      \"method\": \"Radiation dose–response experiments in cancer cells, siRNA knockdown, cGAS/STING pathway reporter assays, mouse tumor models, T cell depletion experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods in vitro and in vivo, functional knockdown, pathway dissection, widely replicated concept\",\n      \"pmids\": [\"28598415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TREX1 suppresses L1 retrotransposon activity through a nuclease-independent mechanism. TREX1 interacts with L1 ORF1p protein and alters its intracellular localization, triggering ORF1p depletion and reducing L1-mediated nicking of genomic DNA. AGS-associated TREX1 mutants competent for DNA exonuclease activity are deficient in inducing ORF1p depletion.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence co-localization, L1 retrotransposition and genomic nicking assays, AGS mutant analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP and functional retrotransposition assays, mechanistic claim of protein destabilization, single lab with two orthogonal methods\",\n      \"pmids\": [\"28334850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"During mitosis, TREX1 is predominantly phosphorylated at C-terminal Serine-261 by Cyclin B/CDK1, and dephosphorylated at mitotic exit likely by PP1/PP2-type phosphatases. Mitotic phosphorylation does not affect DNase activity but phosphomimetic mutations disrupt TREX1 interaction with OST subunit RPN1 and elevate a glyco-gene expression signature. Thus cell-cycle-dependent phosphorylation regulates TREX1's OST-interacting function.\",\n      \"method\": \"Mass spectrometry identification of phosphorylation site, CDK1 inhibition, phosphomimetic mutant co-immunoprecipitation with RPN1, RNA-seq of Trex1⁻/⁻ MEFs with WT or phospho-mutants\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS identification of PTM + Co-IP with mutants + transcriptomic functional readout, multiple orthogonal approaches, single lab\",\n      \"pmids\": [\"28297665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TREX1 transcription is induced by IFN-γ in primary macrophages via STAT1 binding to IFN-γ activation site (GAS) boxes in the Trex1 promoter, and c-Jun (but not c-Fos, JunB, or CREB) binding to an AP-1 box. This was confirmed using STAT1 KO macrophages and EMSA/ChIP assays.\",\n      \"method\": \"EMSA, ChIP, transient transfection reporter assays, STAT1 KO macrophages, promoter mutational analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and EMSA with genetic KO confirmation, promoter mutagenesis, multiple orthogonal approaches\",\n      \"pmids\": [\"21239708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structures of TREX1 complexed with various DNA substrates (L-shaped, Y-shaped DNA) reveal that the Leu24-Pro25-Ser26 cluster serves to cap the non-scissile 5'-end for precise removal of short 3'-overhangs or to wedge into dsDNA for further digestion along the duplex. Arg128 shows consistent interaction patterns with the non-scissile strand across all structures. TREX1 can degrade dsDNA to completion.\",\n      \"method\": \"X-ray crystallography of multiple TREX1-DNA complexes, in vitro biochemical dsDNA degradation assays\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple crystal structures with different substrates combined with biochemical validation, single lab but comprehensive structural analysis\",\n      \"pmids\": [\"29734329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Tumor-derived exosomes from irradiated cancer cells (RT-TEX) transfer dsDNA to dendritic cells and stimulate STING-dependent IFN-β production. The IFN-stimulatory dsDNA cargo of RT-TEX is regulated by TREX1 expression in the parent cancer cells, demonstrating that TREX1 controls the immunostimulatory DNA content packaged into exosomes.\",\n      \"method\": \"Exosome purification and characterization, TREX1 knockdown in cancer cells, DC stimulation assays, in vivo tumor vaccination experiments\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — functional exosome transfer assays with TREX1 KD, in vivo validation, single lab\",\n      \"pmids\": [\"29907693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"cGAS-DNA phase separation inhibits TREX1-mediated DNA degradation. cGAS phase separation forms a selective environment that suppresses TREX1 catalytic function and restricts DNA degradation to the droplet periphery. An AGS-associated TREX1 mutation increases TREX1 penetration into the repressive droplet interior, specifically impairing degradation of phase-separated DNA.\",\n      \"method\": \"In vitro phase separation reconstitution, TREX1 activity assays on phase-separated DNA, confocal imaging of droplets, disease mutant analysis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of phase separation with direct enzymatic activity measurements, disease mutant mechanistic analysis, single lab with multiple methods\",\n      \"pmids\": [\"33606975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The ER-associated nuclease TREX1 inhibits cGAS activation at micronuclei by degrading micronuclear DNA upon micronuclear envelope rupture. The ER accesses ruptured micronuclei enabling TREX1 nucleolytic attack. TREX1 mutations that cause immune disease untether TREX1 from the ER, disrupt localization to micronuclei, diminish micronuclear DNA damage, and enhance cGAS activation. ER tethering is thus mechanistically required for TREX1's role in preventing innate immune activation at micronuclei.\",\n      \"method\": \"Micronuclei purification, TREX1 localization by immunofluorescence, ER membrane tracking, disease mutant analysis, cGAS activation assays, functional nuclease activity at micronuclei\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization experiments with functional consequence, disease mutant mechanistic analysis, micronuclei purification approach, multiple orthogonal methods\",\n      \"pmids\": [\"33476576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TREX1 translocates into the nucleus after nuclear envelope rupture and is required to induce DNA damage in this context. Inside the mammary duct, cellular crowding leads to nuclear envelope ruptures that generate TREX1-dependent DNA damage, driving progression of in situ carcinoma to the invasive stage.\",\n      \"method\": \"Live-cell imaging, TREX1 nuclear translocation assays after NE rupture, TREX1 KO/knockdown, in vivo mammary duct compression models, DNA damage markers\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization tied to functional DNA damage consequence, KO with specific phenotypic readout, multiple orthogonal methods\",\n      \"pmids\": [\"34551315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal structures of human TREX1 in apo (1.25 Å) and DNA-bound (2.2 Å) conformations establish complete solvation of the exonuclease active site and identify specific substitutions involved in DNA recognition. Mapping of all human disease-associated mutations identifies distinct categories affecting enzymatic function, protein stability, and interaction with cGAS-DNA liquid droplets.\",\n      \"method\": \"X-ray crystallography at 1.25 Å (apo) and 2.2 Å (DNA complex), comprehensive mutation mapping\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structures of human (not mouse) protein providing complete active-site model, comprehensive disease mutation analysis\",\n      \"pmids\": [\"35879334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TREX1 degrades the 3' end of the small excised damage-containing DNA oligonucleotides (~30 nt, sedDNA) produced by nucleotide excision repair. TREX1 knockdown increases sedDNA levels and their association with NER proteins TFIIH and RPA; overexpression of WT but not nuclease-inactive TREX1 diminishes sedDNA levels. Purified TREX1 efficiently degrades DNA 3' of UV photoproducts in sedDNA. TREX1 modulation does not affect NER efficiency or cell survival.\",\n      \"method\": \"RNAi screen, TREX1 knockdown/overexpression in UV-irradiated cells, in vitro assays with purified TREX1 and synthetic sedDNA substrates\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro reconstitution with purified enzyme plus cell-based knockdown/overexpression, two orthogonal approaches identifying a new TREX1 substrate\",\n      \"pmids\": [\"35357486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Purified human TREX1 repairs 3'-PUA-peptide/protein DNA-protein cross-links (DPCs) arising from abasic sites, acting as an exonuclease on the 3'-PUA-modified terminus. TREX1 can directly repair 3'-PUA-histone DPCs but not 3'-PUA-PARP1 DPCs unless proteolysis occurs first. Kinetic constants were determined for DPC repair by TREX1.\",\n      \"method\": \"In vitro enzymatic assays with purified recombinant TREX1 and synthetic 3'-PUA-peptide adducts, kinetic analysis, histone and PARP1 DPC substrates\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro reconstitution with purified enzyme on defined synthetic substrates, kinetic characterization, single lab\",\n      \"pmids\": [\"35349719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREX1 can digest ssRNA and DNA/RNA hybrids but not dsRNA. Crystal structures of TREX1-RNA product and TREX1-nucleotide complexes show 2'-OH does not impose steric hindrance for RNA recognition. MD simulations and binding affinity measurements with synthetic DNA-RNA junctions demonstrate that 2'-OH-mediated intra-chain hydrogen bonding in RNA increases conformational rigidity, reducing TREX1 binding affinity and catalytic cleavage efficiency.\",\n      \"method\": \"In vitro exonuclease activity assays, X-ray crystallography, all-atom molecular dynamics simulations, binding affinity measurements\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures combined with MD simulations and biochemical activity measurements, multiple orthogonal approaches\",\n      \"pmids\": [\"37870446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TREX1 degrades cytoplasmic mitochondrial DNA (mtDNA) released during influenza virus infection, preventing cGAS/STING-mediated antiviral sensing. Infection triggers release of mtDNA into the cytoplasm; TREX1 metabolizes this self-DNA, thereby preventing amplification of antiviral signaling and thus aiding viral replication.\",\n      \"method\": \"CRISPR-based genome-wide fitness screen during influenza infection, TREX1 KO cells, mtDNA accumulation assays, cGAS/STING pathway reporters\",\n      \"journal\": \"Cell host & microbe\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide CRISPR screen plus KO validation with specific pathway readout and mtDNA substrate identification, single lab\",\n      \"pmids\": [\"37652009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREX1 expression is coordinately induced with STING by autocrine IFN and downstream STAT1 in cancer cells, acting as a negative feedback mechanism. TREX1 restrains STING-dependent nucleic acid sensing via its catalytic DNA-degrading function. TREX1 inactivation in cancer cells unleashes STING-IFN signaling, recruiting T cells and NK cells and cooperating with PD-1 blockade.\",\n      \"method\": \"Cancer cell TREX1 KO/knockdown, STING pathway reporter assays, in vivo mouse tumor models with immune cell depletion, RNA-seq, combination immunotherapy experiments\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple cancer cell KO models in vitro and in vivo, mechanistic pathway dissection (STAT1→TREX1 induction), immune cell depletion experiments\",\n      \"pmids\": [\"38227896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREX1 C-terminal frameshift variants associated with RVCL mislocalize to the nucleus (due to deletion of the ER-anchoring domain) and inhibit homology-directed repair (HDR), causing DNA deletions. RVCL TREX1 mutants increase cellular vulnerability to DNA damage induced by chemotherapy and cytokines, and cells expressing these mutants are depleted in vivo. Mechanistic studies in Drosophila, mice, and human cells confirm nuclear TREX1 causes DNA damage and disrupts HDR.\",\n      \"method\": \"RVCL patient cell analysis, mouse models, Drosophila genetics, CRISPR HDR assays, DNA damage marker analysis, PARP inhibitor sensitivity assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multi-organism validation (human, mouse, Drosophila) with multiple orthogonal assays linking nuclear TREX1 mislocalization to HDR deficiency and DNA damage\",\n      \"pmids\": [\"38824133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREX1 degrades single-stranded and linearized double-stranded DNA repair templates used for CRISPR-Cas9-mediated HDR, reducing HDR efficiency. TREX1 expression level serves as a biomarker for HDR efficiency across cell types. TREX1 knockout or use of chemically protected ssDNA templates rescues HDR efficiency by 2- to 8-fold in TREX1-expressing cells including primary T cells and hematopoietic stem/progenitor cells.\",\n      \"method\": \"Genome-wide CRISPR screen for HDR suppressors in Fanconi anemia lymphoblasts, TREX1 KO in multiple cell types, HDR efficiency assays with protected vs. unprotected templates\",\n      \"journal\": \"Nature biotechnology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide screen plus KO validation in multiple cell types with direct HDR mechanistic readout, functional rescue with protected templates\",\n      \"pmids\": [\"39134754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Arg-62 residues of TREX1 extend across the dimer interface into the active site of the opposing protomer to coordinate substrate DNA and affect catalysis in trans. The TREX1(R62A/R62A) homodimer exhibits ~50-fold reduced ssDNA and dsDNA degradation. Dominant mutants (D18H, D18N, D200H, D200N) compound heterodimers with R62A in the opposing protomer show higher activity than the corresponding homodimers, demonstrating that Arg-62 provides structural elements required for full catalytic activity in the opposing protomer.\",\n      \"method\": \"Site-directed mutagenesis, recombinant homo- and heterodimer preparation, in vitro ssDNA and dsDNA exonuclease activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro biochemical reconstitution with multiple mutant combinations, mechanistic dissection of dimer interface trans-catalysis\",\n      \"pmids\": [\"24616097\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TREX1 is an ER-anchored, dimeric 3'→5' DNA exonuclease (and weak exoribonuclease) that constitutively degrades cytosolic ssDNA, dsDNA, reverse-transcribed DNA, RNA, DNA/RNA hybrids, and NER-excised oligonucleotides to prevent cGAS-STING-dependent innate immune activation; its ER tethering—regulated by a C-terminal transmembrane domain subject to mitotic CDK1 phosphorylation and ubiquitination—directs it to ruptured micronuclei and nuclear envelope rupture sites where it resects DNA to limit cGAS access, while a nuclease-independent C-terminal interaction with the oligosaccharyltransferase (OST) complex suppresses glycan-driven immune activation, and loss-of-function or mislocalization of TREX1 results in cytosolic DNA accumulation sensed by cGAS, driving type I IFN-dependent autoimmune disease.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TREX1 is the major mammalian 3'\\u21925' DNA exonuclease, a homodimer with a DEDDh-family active site that constitutively degrades cytosolic DNA to prevent cell-autonomous innate immune activation [#0, #1, #3]. Biochemically it excises 3'-terminal nucleotides from single-stranded DNA, nicked and blunt dsDNA, and reverse-transcribed DNA, processively melting and digesting duplex substrates to completion via residues including Arg128, Arg174/Lys175, and the Leu24-Pro25-Ser26 cap [#9, #15, #30]; crystal structures of substrate/product complexes establish the molecular basis for 3'-nucleotide specificity and DNA strand separation [#5, #23, #35]. The dimer interface is functionally integrated, with Arg62 and Arg114 acting in trans across protomers, which explains how dominant-negative disease heterodimers inactivate wild-type enzyme [#16, #43]. Beyond DNA, TREX1 is also an exoribonuclease degrading ssRNA and DNA/RNA hybrids but not dsRNA, with RNA's 2'-OH-driven rigidity reducing catalytic efficiency [#22, #38]. The enzyme functions as an essential negative regulator of the interferon-stimulatory DNA response: loss of TREX1 causes accumulation of endogenous retroelement-derived, micronuclear, and mitochondrial DNA that is sensed by cGAS, driving STING/TBK1/IRF3-dependent type I IFN and lethal autoimmunity, with cGAS deletion fully rescuing the Trex1\\u207b/\\u207b phenotype [#8, #20, #25, #39]. TREX1 is normally ER-anchored through a C-terminal transmembrane domain; this tethering directs it to ruptured micronuclei and nuclear envelope rupture sites to resect exposed DNA and limit cGAS access, and disease mutations that untether the enzyme abolish this localization [#33, #34]. A separate, nuclease-independent C-terminal interaction with the ER oligosaccharyltransferase (OST) complex \\u2014 regulated by mitotic CDK1 phosphorylation at Ser261 \\u2014 stabilizes OST and suppresses glycan-driven immune activation [#24, #28]. TREX1 loss-of-function or C-terminal frameshift mutations cause Aicardi-Goutieres syndrome, familial chilblain lupus, systemic lupus-like disease, and retinal vasculopathy with cerebral leukodystrophy (RVCL), the latter through nuclear mislocalization that disrupts homology-directed repair [#3, #23, #24, #41].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established that TREX1 is an autonomous 3'\\u21925' DNA exonuclease, defining the molecular activity that anchors all later biology.\",\n      \"evidence\": \"Recombinant protein from E. coli with in vitro exonuclease assays on multiple substrates\",\n      \"pmids\": [\"10391904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cellular substrate or physiological role identified\", \"Initially reported no RNA activity, later revised\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed TREX1 acts as a homodimer with rigorous kinetics and defined substrate-structure preferences, framing its enzymatic mechanism.\",\n      \"evidence\": \"Purified mouse Trex1, steady-state kinetics, heparin competition assays\",\n      \"pmids\": [\"11279105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dimer interface contributions to catalysis not yet resolved\", \"No in vivo function\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated that TREX1 loss in vivo causes inflammatory disease rather than mutator/cancer phenotype, redirecting the field toward immune regulation.\",\n      \"evidence\": \"Trex1\\u207b/\\u207b knockout mice, histopathology, survival analysis\",\n      \"pmids\": [\"15254239\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger of inflammation unknown\", \"Sensor pathway not yet identified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked TREX1 to human Aicardi-Goutieres syndrome and to a SET-complex apoptotic DNA-degradation role, connecting enzyme activity to disease and to genomic DNA clearance.\",\n      \"evidence\": \"AGS mutation activity assays, Trex1\\u207b/\\u207b mice, reciprocal Co-IP with SET/NM23-H1, granzyme A cell death assays\",\n      \"pmids\": [\"16845398\", \"16818237\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nature of the immune-triggering DNA species undefined\", \"Relationship between apoptotic and homeostatic roles unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Provided crystal structures and the dominant-versus-recessive biochemical logic, explaining at atomic resolution why disease mutants lose activity and how dominant heterodimers poison wild-type enzyme.\",\n      \"evidence\": \"X-ray crystallography of substrate/product complexes, NMR, mutant homo/heterodimer activity assays, CA150 Co-IP\",\n      \"pmids\": [\"17293595\", \"17355961\", \"17440703\", \"18805785\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo substrate still not pinned down\", \"Functional relevance of CA150/proline-rich interactions untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined TREX1 as an essential negative regulator of the ISD response that metabolizes reverse-transcribed and replication-derived ssDNA, establishing its homeostatic innate-immune function.\",\n      \"evidence\": \"Genetic ISD pathway analysis, Trex1\\u207b/\\u207b cells, retroelement DNA accumulation, ER-to-nucleus relocalization after genotoxic stress\",\n      \"pmids\": [\"18724932\", \"18045533\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream sensor not yet identified\", \"Mechanism of stress-induced relocalization unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Resolved the catalytic-impairment mechanism of disease mutants and identified catalytic metal/residue requirements, refining the structural enzymology.\",\n      \"evidence\": \"X-ray crystallography of apo and mutant TREX1, His124 mutagenesis, cation inhibition structures\",\n      \"pmids\": [\"22071149\", \"18780819\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Connection of structural defects to cellular phenotype indirect\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed TREX1 degrades cytosolic HIV reverse-transcribed DNA to suppress type I IFN, extending its substrate range to retroviral DNA and revealing the TBK1/STING/IRF3 axis.\",\n      \"evidence\": \"Trex1\\u207b/\\u207b cells, human T-cell/macrophage RNAi, Co-IP of TREX1 with HIV DNA, IFN induction assays\",\n      \"pmids\": [\"20871604\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether degradation is direct on viral DNA or via accessory factors not fully resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established stress-responsive and cytokine-responsive transcriptional control of TREX1 by AP-1, STAT1, and IFN-\\u03b3, embedding the enzyme in feedback regulation.\",\n      \"evidence\": \"Promoter reporters, EMSA, ChIP, c-fos/c-jun and STAT1 null cells\",\n      \"pmids\": [\"20511593\", \"21239708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of induction to disease protection unmeasured\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Dissected the dsDNA-degradation mechanism at endonuclease-generated 3' termini and the metal-dependent dominant-inhibition mechanism, explaining dominant autoimmune phenotypes.\",\n      \"evidence\": \"In vitro plasmid/chromatin dsDNA assays, mutant competition assays\",\n      \"pmids\": [\"21808053\", \"21937424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo source of endonuclease-generated termini unspecified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Revealed a type-I-IFN-independent arm of TREX1 deficiency involving lysosomal biogenesis, TFEB, and mTORC1, broadening its cellular impact beyond IFN.\",\n      \"evidence\": \"Trex1\\u207b/\\u207b cells, STING/TBK1/IRF3/IRF7 epistasis, transcriptomics, lysosomal analysis\",\n      \"pmids\": [\"23160154\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between DNA clearance and lysosomal/mTORC1 changes unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified C-terminal ubiquitination and ubiquilin-1 binding as determinants of TREX1 subcellular localization, introducing post-translational control of trafficking.\",\n      \"evidence\": \"Deletion constructs, MS proteomics, Co-IP, co-localization\",\n      \"pmids\": [\"23979357\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of ubiquilin-1-directed punctae untested\", \"Ubiquitin ligase unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed that oxidative DNA modification (8-OHG) renders DNA resistant to TREX1, providing a mechanism by which damaged self/pathogen DNA escapes clearance and activates cGAS-STING.\",\n      \"evidence\": \"In vitro degradation assays with oxidized DNA, cytosolic sensing assays\",\n      \"pmids\": [\"23993650\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of 8-OHG resistance to autoimmunity not quantified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Placed cGAS as the required sensor downstream of TREX1 loss both in cells and in vivo, defining the genetic backbone of TREX1-deficiency disease.\",\n      \"evidence\": \"TREX1/cGAS double-knockout cells and mice, ISG and autoantibody readouts\",\n      \"pmids\": [\"24813208\", \"26223655\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific drivers of inflammation not dissected\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined a trans-acting dimer-interface residue (Arg62) and a PARP1 interaction, refining dimer catalysis and hinting at DNA-damage-response roles.\",\n      \"evidence\": \"Mutant heterodimer activity assays; MS, Co-IP, domain mapping for PARP1\",\n      \"pmids\": [\"24616097\", \"25278026\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PARP1 stabilization claim is partial/suggestive from a single lab\", \"Functional role of nuclear TREX1-PARP1 interaction unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Expanded TREX1 to an exoribonuclease, defined the dsDNA-unwinding mechanism in a knock-in lupus model, and uncovered the nuclease-independent OST-complex function, separating TREX1's two distinct activities.\",\n      \"evidence\": \"In vitro RNA assays, D18N-dsDNA crystal structure with D18N knock-in mice, OST Co-IP with frameshift mice/patient cells and aclacinomycin rescue\",\n      \"pmids\": [\"25855793\", \"25848017\", \"26320659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological RNA substrates of TREX1 in vivo unidentified\", \"How OST interaction integrates with nuclease function unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established TREX1 as a cell-cycle-regulated (CDK1/Ser261) and radiation-induced enzyme that restrains tumor immunogenicity and suppresses L1 retrotransposons by a nuclease-independent ORF1p mechanism.\",\n      \"evidence\": \"MS phosphosite mapping with phosphomimetics, radiation dose-response with cGAS/STING readouts and tumor models, ORF1p Co-IP and L1 retrotransposition assays\",\n      \"pmids\": [\"28297665\", \"28598415\", \"28334850\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"L1 ORF1p depletion mechanism (single lab, two methods) needs reciprocal validation\", \"Phosphatase identity at mitotic exit inferred not proven\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided comprehensive structural views of TREX1 on branched DNA substrates showing capping and processive duplex digestion, and linked TREX1 to immunostimulatory exosome DNA cargo.\",\n      \"evidence\": \"Crystal structures of multiple TREX1-DNA complexes; exosome transfer and DC stimulation assays with TREX1 KD\",\n      \"pmids\": [\"29734329\", \"29907693\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exosome study is medium-confidence single-lab; in vivo generality untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed that ER tethering directs TREX1 to ruptured micronuclei and NE-rupture sites for DNA resection, that cGAS phase separation locally shields DNA from TREX1, and that nuclear TREX1 can itself drive DNA damage and cancer progression.\",\n      \"evidence\": \"Micronuclei purification with ER tracking and disease-mutant analysis, in vitro cGAS-DNA phase-separation reconstitution, live imaging of NE rupture in mammary duct models\",\n      \"pmids\": [\"33476576\", \"33606975\", \"34551315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ER membrane gains access to ruptured envelopes mechanistically unresolved\", \"Balance between protective resection and damaging nuclear activity context-dependent\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Delivered the high-resolution human TREX1 structure with full disease-mutation mapping and assigned new substrate activities (NER sedDNA, 3'-PUA DNA-protein cross-links), broadening TREX1's role in DNA repair processing.\",\n      \"evidence\": \"Human apo (1.25 \\u00c5) and DNA-bound crystal structures; in vitro and cell assays with sedDNA; purified-enzyme DPC repair kinetics\",\n      \"pmids\": [\"35879334\", \"35357486\", \"35349719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo importance of sedDNA/DPC processing for genome stability unquantified\", \"Whether these activities feed cGAS signaling untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the structural/dynamic basis for TREX1 RNA discrimination and showed TREX1 clears virus-released cytoplasmic mitochondrial DNA to dampen antiviral sensing.\",\n      \"evidence\": \"Crystal structures, MD simulations and binding affinities on DNA/RNA junctions; CRISPR fitness screen and KO with mtDNA/cGAS-STING readouts during influenza infection\",\n      \"pmids\": [\"37870446\", \"37652009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of mtDNA clearance across other infections untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established TREX1 as a STAT1-driven negative-feedback brake on STING signaling exploitable for immunotherapy, and showed RVCL frameshift mutants mislocalize to the nucleus to impair HDR while TREX1 broadly limits CRISPR HDR template availability.\",\n      \"evidence\": \"Cancer-cell KO with in vivo tumor/PD-1 models; multi-organism (human/mouse/Drosophila) RVCL mutant HDR assays; genome-wide CRISPR HDR screen with protected-template rescue\",\n      \"pmids\": [\"38227896\", \"38824133\", \"39134754\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Therapeutic window of TREX1 inhibition versus autoimmunity risk undefined\", \"How nuclear mislocalization mechanistically blocks HDR not fully resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TREX1's distinct activities \\u2014 cytosolic DNA/RNA degradation, ER-tethered micronuclear resection, nuclease-independent OST stabilization, and DNA-repair processing \\u2014 are coordinated and prioritized in a single cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of how localization, PTMs, and partner interactions partition TREX1 between protective and pathogenic functions\", \"Physiological RNA and DPC substrates in vivo unidentified\", \"Mechanism coupling DNA clearance to lysosomal/mTORC1 program unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [0, 1, 5, 9, 15, 30, 35, 36, 37]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 9, 22, 38]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [22, 38]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [5, 15, 23, 30, 35]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [22, 38]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4, 10, 24, 33]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 10, 14, 21, 34, 41]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 13, 20, 39]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 13, 17, 20, 25, 26, 39, 40]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [8, 19, 20, 33]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [36, 37, 41, 42]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 23, 24, 41]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 7]}\n    ],\n    \"complexes\": [\n      \"SET complex\",\n      \"oligosaccharyltransferase (OST) complex\"\n    ],\n    \"partners\": [\n      \"SET\",\n      \"NME1/NM23-H1\",\n      \"RPN1\",\n      \"UBQLN1\",\n      \"PARP1\",\n      \"L1 ORF1p\",\n      \"cGAS\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}